JP7486544B2 - Method for producing sheet-shaped cell culture - Google Patents
Method for producing sheet-shaped cell culture Download PDFInfo
- Publication number
- JP7486544B2 JP7486544B2 JP2022078617A JP2022078617A JP7486544B2 JP 7486544 B2 JP7486544 B2 JP 7486544B2 JP 2022078617 A JP2022078617 A JP 2022078617A JP 2022078617 A JP2022078617 A JP 2022078617A JP 7486544 B2 JP7486544 B2 JP 7486544B2
- Authority
- JP
- Japan
- Prior art keywords
- cell culture
- cells
- culture
- serum
- sheet
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000004113 cell culture Methods 0.000 title claims description 149
- 238000004519 manufacturing process Methods 0.000 title claims description 39
- 210000004027 cell Anatomy 0.000 claims description 140
- 239000000758 substrate Substances 0.000 claims description 45
- 238000000034 method Methods 0.000 claims description 43
- 210000004683 skeletal myoblast Anatomy 0.000 claims description 32
- 108090000695 Cytokines Proteins 0.000 claims description 23
- 102000004127 Cytokines Human genes 0.000 claims description 23
- 230000004069 differentiation Effects 0.000 claims description 18
- 238000010899 nucleation Methods 0.000 claims description 18
- 230000002757 inflammatory effect Effects 0.000 claims description 15
- 210000005088 multinucleated cell Anatomy 0.000 claims description 6
- 108091003079 Bovine Serum Albumin Proteins 0.000 claims description 4
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 claims description 3
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 claims description 3
- 230000001939 inductive effect Effects 0.000 claims description 3
- 229940098773 bovine serum albumin Drugs 0.000 claims 2
- 210000002966 serum Anatomy 0.000 description 108
- 239000000306 component Substances 0.000 description 34
- 239000003102 growth factor Substances 0.000 description 34
- 239000001963 growth medium Substances 0.000 description 30
- 150000003431 steroids Chemical class 0.000 description 21
- 239000000126 substance Substances 0.000 description 21
- 238000005406 washing Methods 0.000 description 21
- 230000000694 effects Effects 0.000 description 19
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 15
- 108090000623 proteins and genes Proteins 0.000 description 15
- 229910052711 selenium Inorganic materials 0.000 description 15
- 239000011669 selenium Substances 0.000 description 15
- 239000006143 cell culture medium Substances 0.000 description 14
- 239000000463 material Substances 0.000 description 13
- 102000004420 Creatine Kinase Human genes 0.000 description 12
- 108010042126 Creatine kinase Proteins 0.000 description 12
- 239000002609 medium Substances 0.000 description 12
- 230000000735 allogeneic effect Effects 0.000 description 11
- 239000011248 coating agent Substances 0.000 description 11
- 239000012535 impurity Substances 0.000 description 11
- 235000018102 proteins Nutrition 0.000 description 11
- 102000004169 proteins and genes Human genes 0.000 description 11
- 238000002054 transplantation Methods 0.000 description 11
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 10
- 238000000576 coating method Methods 0.000 description 9
- 239000012228 culture supernatant Substances 0.000 description 9
- 230000002411 adverse Effects 0.000 description 8
- 239000007640 basal medium Substances 0.000 description 8
- 150000001875 compounds Chemical class 0.000 description 8
- -1 polyethylene Polymers 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 7
- 238000012258 culturing Methods 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 239000013543 active substance Substances 0.000 description 6
- 230000004663 cell proliferation Effects 0.000 description 6
- 238000007654 immersion Methods 0.000 description 6
- 238000011534 incubation Methods 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 230000035755 proliferation Effects 0.000 description 6
- 230000009467 reduction Effects 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 5
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 5
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 5
- 239000000654 additive Substances 0.000 description 5
- 230000033115 angiogenesis Effects 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 241000894007 species Species 0.000 description 5
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 5
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 4
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 4
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 4
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 4
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 4
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 4
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 4
- 239000012980 RPMI-1640 medium Substances 0.000 description 4
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 4
- 150000003926 acrylamides Chemical class 0.000 description 4
- 238000013019 agitation Methods 0.000 description 4
- 239000007853 buffer solution Substances 0.000 description 4
- 238000007796 conventional method Methods 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 239000012091 fetal bovine serum Substances 0.000 description 4
- 229940126864 fibroblast growth factor Drugs 0.000 description 4
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 4
- 230000014509 gene expression Effects 0.000 description 4
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 238000013518 transcription Methods 0.000 description 4
- 230000035897 transcription Effects 0.000 description 4
- 102000009024 Epidermal Growth Factor Human genes 0.000 description 3
- 101800003838 Epidermal growth factor Proteins 0.000 description 3
- 108090000176 Interleukin-13 Proteins 0.000 description 3
- 108090000978 Interleukin-4 Proteins 0.000 description 3
- 108010002616 Interleukin-5 Proteins 0.000 description 3
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 3
- 229940024606 amino acid Drugs 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 230000030833 cell death Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 229960003957 dexamethasone Drugs 0.000 description 3
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 3
- 229940116977 epidermal growth factor Drugs 0.000 description 3
- 208000019622 heart disease Diseases 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 230000002107 myocardial effect Effects 0.000 description 3
- 230000000704 physical effect Effects 0.000 description 3
- 239000002504 physiological saline solution Substances 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 210000002027 skeletal muscle Anatomy 0.000 description 3
- 230000007704 transition Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 239000001763 2-hydroxyethyl(trimethyl)azanium Substances 0.000 description 2
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 2
- 206010001367 Adrenal insufficiency Diseases 0.000 description 2
- 108010081589 Becaplermin Proteins 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 235000019743 Choline chloride Nutrition 0.000 description 2
- 208000014311 Cushing syndrome Diseases 0.000 description 2
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 206010019280 Heart failures Diseases 0.000 description 2
- FFEARJCKVFRZRR-UHFFFAOYSA-N L-Methionine Natural products CSCCC(N)C(O)=O FFEARJCKVFRZRR-UHFFFAOYSA-N 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 2
- 229930064664 L-arginine Natural products 0.000 description 2
- 235000014852 L-arginine Nutrition 0.000 description 2
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 2
- 239000004158 L-cystine Substances 0.000 description 2
- 235000019393 L-cystine Nutrition 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- 229930182816 L-glutamine Natural products 0.000 description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
- 229930182844 L-isoleucine Natural products 0.000 description 2
- 239000004395 L-leucine Substances 0.000 description 2
- 235000019454 L-leucine Nutrition 0.000 description 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- 229930195722 L-methionine Natural products 0.000 description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 2
- 206010028851 Necrosis Diseases 0.000 description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- 238000000636 Northern blotting Methods 0.000 description 2
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 2
- 102000006382 Ribonucleases Human genes 0.000 description 2
- 108010083644 Ribonucleases Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 238000002105 Southern blotting Methods 0.000 description 2
- JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 2
- 239000004473 Threonine Substances 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 208000017515 adrenocortical insufficiency Diseases 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 229960002537 betamethasone Drugs 0.000 description 2
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 description 2
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 2
- 244000309466 calf Species 0.000 description 2
- 210000004413 cardiac myocyte Anatomy 0.000 description 2
- 230000024245 cell differentiation Effects 0.000 description 2
- SGMZJAMFUVOLNK-UHFFFAOYSA-M choline chloride Chemical compound [Cl-].C[N+](C)(C)CCO SGMZJAMFUVOLNK-UHFFFAOYSA-M 0.000 description 2
- 229960003178 choline chloride Drugs 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- 229960003067 cystine Drugs 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000003792 electrolyte Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000010195 expression analysis Methods 0.000 description 2
- 229960000304 folic acid Drugs 0.000 description 2
- 235000019152 folic acid Nutrition 0.000 description 2
- 239000011724 folic acid Substances 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 229960002885 histidine Drugs 0.000 description 2
- 229960000890 hydrocortisone Drugs 0.000 description 2
- 238000003365 immunocytochemistry Methods 0.000 description 2
- 238000003364 immunohistochemistry Methods 0.000 description 2
- 238000001114 immunoprecipitation Methods 0.000 description 2
- 238000007901 in situ hybridization Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 2
- 229960000310 isoleucine Drugs 0.000 description 2
- 229960003136 leucine Drugs 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 229960004452 methionine Drugs 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- QNILTEGFHQSKFF-UHFFFAOYSA-N n-propan-2-ylprop-2-enamide Chemical compound CC(C)NC(=O)C=C QNILTEGFHQSKFF-UHFFFAOYSA-N 0.000 description 2
- 230000017074 necrotic cell death Effects 0.000 description 2
- 229960003966 nicotinamide Drugs 0.000 description 2
- 235000005152 nicotinamide Nutrition 0.000 description 2
- 239000011570 nicotinamide Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 2
- 108010000685 platelet-derived growth factor AB Proteins 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 2
- 229960005205 prednisolone Drugs 0.000 description 2
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 2
- 201000009395 primary hyperaldosteronism Diseases 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000002331 protein detection Methods 0.000 description 2
- 238000005086 pumping Methods 0.000 description 2
- KIDHWZJUCRJVML-UHFFFAOYSA-N putrescine Chemical compound NCCCCN KIDHWZJUCRJVML-UHFFFAOYSA-N 0.000 description 2
- 235000008160 pyridoxine Nutrition 0.000 description 2
- 239000011677 pyridoxine Substances 0.000 description 2
- 238000003127 radioimmunoassay Methods 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- 230000001172 regenerating effect Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- 235000019192 riboflavin Nutrition 0.000 description 2
- 229960002477 riboflavin Drugs 0.000 description 2
- 239000002151 riboflavin Substances 0.000 description 2
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 229960001153 serine Drugs 0.000 description 2
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 235000019157 thiamine Nutrition 0.000 description 2
- 229960003495 thiamine Drugs 0.000 description 2
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 description 2
- 239000011721 thiamine Substances 0.000 description 2
- 229960002898 threonine Drugs 0.000 description 2
- 229960005294 triamcinolone Drugs 0.000 description 2
- GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 description 2
- 229960004441 tyrosine Drugs 0.000 description 2
- 229960004295 valine Drugs 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940011671 vitamin b6 Drugs 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- XLPJNCYCZORXHG-UHFFFAOYSA-N 1-morpholin-4-ylprop-2-en-1-one Chemical compound C=CC(=O)N1CCOCC1 XLPJNCYCZORXHG-UHFFFAOYSA-N 0.000 description 1
- RESPXSHDJQUNTN-UHFFFAOYSA-N 1-piperidin-1-ylprop-2-en-1-one Chemical compound C=CC(=O)N1CCCCC1 RESPXSHDJQUNTN-UHFFFAOYSA-N 0.000 description 1
- WLPAQAXAZQUXBG-UHFFFAOYSA-N 1-pyrrolidin-1-ylprop-2-en-1-one Chemical compound C=CC(=O)N1CCCC1 WLPAQAXAZQUXBG-UHFFFAOYSA-N 0.000 description 1
- VKUYLANQOAKALN-UHFFFAOYSA-N 2-[benzyl-(4-methoxyphenyl)sulfonylamino]-n-hydroxy-4-methylpentanamide Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N(C(CC(C)C)C(=O)NO)CC1=CC=CC=C1 VKUYLANQOAKALN-UHFFFAOYSA-N 0.000 description 1
- QDGAVODICPCDMU-UHFFFAOYSA-N 2-amino-3-[3-[bis(2-chloroethyl)amino]phenyl]propanoic acid Chemical compound OC(=O)C(N)CC1=CC=CC(N(CCCl)CCCl)=C1 QDGAVODICPCDMU-UHFFFAOYSA-N 0.000 description 1
- AKVUWTYSNLGBJY-UHFFFAOYSA-N 2-methyl-1-morpholin-4-ylprop-2-en-1-one Chemical compound CC(=C)C(=O)N1CCOCC1 AKVUWTYSNLGBJY-UHFFFAOYSA-N 0.000 description 1
- RASDUGQQSMMINZ-UHFFFAOYSA-N 2-methyl-1-piperidin-1-ylprop-2-en-1-one Chemical compound CC(=C)C(=O)N1CCCCC1 RASDUGQQSMMINZ-UHFFFAOYSA-N 0.000 description 1
- LVCMKNCJDCTPIB-UHFFFAOYSA-N 2-methyl-1-pyrrolidin-1-ylprop-2-en-1-one Chemical compound CC(=C)C(=O)N1CCCC1 LVCMKNCJDCTPIB-UHFFFAOYSA-N 0.000 description 1
- JJOYJOCWEDSDOO-UHFFFAOYSA-N 2-methyl-n-(oxolan-2-ylmethyl)prop-2-enamide Chemical compound CC(=C)C(=O)NCC1CCCO1 JJOYJOCWEDSDOO-UHFFFAOYSA-N 0.000 description 1
- YQIGLEFUZMIVHU-UHFFFAOYSA-N 2-methyl-n-propan-2-ylprop-2-enamide Chemical compound CC(C)NC(=O)C(C)=C YQIGLEFUZMIVHU-UHFFFAOYSA-N 0.000 description 1
- CCIDRBFZPRURMU-UHFFFAOYSA-N 2-methyl-n-propylprop-2-enamide Chemical compound CCCNC(=O)C(C)=C CCIDRBFZPRURMU-UHFFFAOYSA-N 0.000 description 1
- 102100026802 72 kDa type IV collagenase Human genes 0.000 description 1
- 101710151806 72 kDa type IV collagenase Proteins 0.000 description 1
- ZKRFOXLVOKTUTA-KQYNXXCUSA-N 9-(5-phosphoribofuranosyl)-6-mercaptopurine Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(O)=O)O[C@H]1N1C(NC=NC2=S)=C2N=C1 ZKRFOXLVOKTUTA-KQYNXXCUSA-N 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- 206010002199 Anaphylactic shock Diseases 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 102100022987 Angiogenin Human genes 0.000 description 1
- 102000009840 Angiopoietins Human genes 0.000 description 1
- 108010009906 Angiopoietins Proteins 0.000 description 1
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 1
- 102100037152 BAG family molecular chaperone regulator 1 Human genes 0.000 description 1
- 101710089792 BAG family molecular chaperone regulator 1 Proteins 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 229910001369 Brass Inorganic materials 0.000 description 1
- 206010056370 Congestive cardiomyopathy Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 201000010046 Dilated cardiomyopathy Diseases 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102100021866 Hepatocyte growth factor Human genes 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 description 1
- 101000898034 Homo sapiens Hepatocyte growth factor Proteins 0.000 description 1
- 101001076408 Homo sapiens Interleukin-6 Proteins 0.000 description 1
- 101000669513 Homo sapiens Metalloproteinase inhibitor 1 Proteins 0.000 description 1
- 101001001487 Homo sapiens Phosphatidylinositol-glycan biosynthesis class F protein Proteins 0.000 description 1
- 101000595923 Homo sapiens Placenta growth factor Proteins 0.000 description 1
- 101000868152 Homo sapiens Son of sevenless homolog 1 Proteins 0.000 description 1
- 101000801260 Homo sapiens Troponin C, slow skeletal and cardiac muscles Proteins 0.000 description 1
- 101000851334 Homo sapiens Troponin I, cardiac muscle Proteins 0.000 description 1
- 101000764260 Homo sapiens Troponin T, cardiac muscle Proteins 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 235000019766 L-Lysine Nutrition 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 1
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 1
- 102100030412 Matrix metalloproteinase-9 Human genes 0.000 description 1
- 108010015302 Matrix metalloproteinase-9 Proteins 0.000 description 1
- 102100039364 Metalloproteinase inhibitor 1 Human genes 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920002302 Nylon 6,6 Polymers 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 1
- 102100035194 Placenta growth factor Human genes 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 239000005700 Putrescine Substances 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 102100030416 Stromelysin-1 Human genes 0.000 description 1
- 101710108790 Stromelysin-1 Proteins 0.000 description 1
- 102100028848 Stromelysin-2 Human genes 0.000 description 1
- 101710108792 Stromelysin-2 Proteins 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 239000004809 Teflon Substances 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- 102100036859 Troponin I, cardiac muscle Human genes 0.000 description 1
- 102100026893 Troponin T, cardiac muscle Human genes 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- QYKIQEUNHZKYBP-UHFFFAOYSA-N Vinyl ether Chemical class C=COC=C QYKIQEUNHZKYBP-UHFFFAOYSA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 108010072788 angiogenin Proteins 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- DMLAVOWQYNRWNQ-UHFFFAOYSA-N azobenzene Chemical group C1=CC=CC=C1N=NC1=CC=CC=C1 DMLAVOWQYNRWNQ-UHFFFAOYSA-N 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 239000010951 brass Substances 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- FDJOLVPMNUYSCM-UVKKECPRSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2,7, Chemical compound [Co+3].N#[C-].C1([C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)[N-]\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O FDJOLVPMNUYSCM-UVKKECPRSA-L 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 239000012531 culture fluid Substances 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000010908 decantation Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940037395 electrolytes Drugs 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 229960002743 glutamine Drugs 0.000 description 1
- 229960002449 glycine Drugs 0.000 description 1
- 229920001519 homopolymer Polymers 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000000021 kinase assay Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- AGBQKNBQESQNJD-UHFFFAOYSA-M lipoate Chemical compound [O-]C(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-M 0.000 description 1
- 235000019136 lipoic acid Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 239000012533 medium component Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- XJRBAMWJDBPFIM-UHFFFAOYSA-N methyl vinyl ether Chemical compound COC=C XJRBAMWJDBPFIM-UHFFFAOYSA-N 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- OVHHHVAVHBHXAK-UHFFFAOYSA-N n,n-diethylprop-2-enamide Chemical compound CCN(CC)C(=O)C=C OVHHHVAVHBHXAK-UHFFFAOYSA-N 0.000 description 1
- KAKALCZDCFZYRN-UHFFFAOYSA-N n-(2-ethoxyethyl)-2-methylprop-2-enamide Chemical compound CCOCCNC(=O)C(C)=C KAKALCZDCFZYRN-UHFFFAOYSA-N 0.000 description 1
- YLQHOUDDHYMERA-UHFFFAOYSA-N n-(2-ethoxyethyl)prop-2-enamide Chemical compound CCOCCNC(=O)C=C YLQHOUDDHYMERA-UHFFFAOYSA-N 0.000 description 1
- KPEKHIHQXHOSRM-UHFFFAOYSA-N n-(oxolan-2-ylmethyl)prop-2-enamide Chemical compound C=CC(=O)NCC1CCCO1 KPEKHIHQXHOSRM-UHFFFAOYSA-N 0.000 description 1
- FIBUWQFQYAAXHD-UHFFFAOYSA-N n-cyclopropyl-2-methylprop-2-enamide Chemical compound CC(=C)C(=O)NC1CC1 FIBUWQFQYAAXHD-UHFFFAOYSA-N 0.000 description 1
- LCXIFAOALNZGDO-UHFFFAOYSA-N n-cyclopropylprop-2-enamide Chemical compound C=CC(=O)NC1CC1 LCXIFAOALNZGDO-UHFFFAOYSA-N 0.000 description 1
- SWPMNMYLORDLJE-UHFFFAOYSA-N n-ethylprop-2-enamide Chemical compound CCNC(=O)C=C SWPMNMYLORDLJE-UHFFFAOYSA-N 0.000 description 1
- WDFKEEALECCKTJ-UHFFFAOYSA-N n-propylprop-2-enamide Chemical compound CCCNC(=O)C=C WDFKEEALECCKTJ-UHFFFAOYSA-N 0.000 description 1
- 239000007793 ph indicator Substances 0.000 description 1
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 1
- 229960005190 phenylalanine Drugs 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920000139 polyethylene terephthalate Polymers 0.000 description 1
- 239000005020 polyethylene terephthalate Substances 0.000 description 1
- 239000004926 polymethyl methacrylate Substances 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 229940082569 selenite Drugs 0.000 description 1
- MCAHWIHFGHIESP-UHFFFAOYSA-L selenite(2-) Chemical compound [O-][Se]([O-])=O MCAHWIHFGHIESP-UHFFFAOYSA-L 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- IFGCUJZIWBUILZ-UHFFFAOYSA-N sodium 2-[[2-[[hydroxy-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyphosphoryl]amino]-4-methylpentanoyl]amino]-3-(1H-indol-3-yl)propanoic acid Chemical compound [Na+].C=1NC2=CC=CC=C2C=1CC(C(O)=O)NC(=O)C(CC(C)C)NP(O)(=O)OC1OC(C)C(O)C(O)C1O IFGCUJZIWBUILZ-UHFFFAOYSA-N 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229940054269 sodium pyruvate Drugs 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- WPLOVIFNBMNBPD-ATHMIXSHSA-N subtilin Chemical compound CC1SCC(NC2=O)C(=O)NC(CC(N)=O)C(=O)NC(C(=O)NC(CCCCN)C(=O)NC(C(C)CC)C(=O)NC(=C)C(=O)NC(CCCCN)C(O)=O)CSC(C)C2NC(=O)C(CC(C)C)NC(=O)C1NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C1NC(=O)C(=C/C)/NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)CNC(=O)C(NC(=O)C(NC(=O)C2NC(=O)CNC(=O)C3CCCN3C(=O)C(NC(=O)C3NC(=O)C(CC(C)C)NC(=O)C(=C)NC(=O)C(CCC(O)=O)NC(=O)C(NC(=O)C(CCCCN)NC(=O)C(N)CC=4C5=CC=CC=C5NC=4)CSC3)C(C)SC2)C(C)C)C(C)SC1)CC1=CC=CC=C1 WPLOVIFNBMNBPD-ATHMIXSHSA-N 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 239000013076 target substance Substances 0.000 description 1
- 229960002663 thioctic acid Drugs 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 230000007838 tissue remodeling Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 229960004799 tryptophan Drugs 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 235000019195 vitamin supplement Nutrition 0.000 description 1
Landscapes
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Materials For Medical Uses (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Description
本発明は、シート状細胞培養物の製造方法、および該製造方法により製造されたシート状細胞培養物に関する。 The present invention relates to a method for producing a sheet-shaped cell culture, and a sheet-shaped cell culture produced by the method.
心臓はそのポンプ機能により全身に酸素を運搬しており、生命の維持に必須の役割を担っている。そのため、心疾患は死亡原因の上位をしめており、狭心症、心筋梗塞などの虚血性心疾患では、心筋組織に十分な酸素が行き渡らなくなり、この状態が長時間つづくと壊死をおこしてしまう。成人の心筋細胞は自己複製能に乏しいため、一度壊死すると再生することはなく心不全に陥ってしまう。このような状態に至ると、左心補助人工心臓を装着するか、最終的には心臓移植を受けるしか治療法がないのが現状である。
このような中で心不全の新たな治療法として研究が進められているのが、心臓への細胞移植である。これまでに、胎児心筋細胞、骨格筋芽細胞、ＥＳ細胞、骨髄由来の細胞等の利用が、動物を用いた実験で報告されている。
The heart transports oxygen to the entire body with its pumping function, and plays an essential role in maintaining life. For this reason, heart disease is one of the leading causes of death. In ischemic heart diseases such as angina pectoris and myocardial infarction, insufficient oxygen reaches the myocardial tissue, and if this condition continues for a long time, necrosis occurs. Since adult cardiac myocytes have poor self-replicating ability, once necrosis occurs, they cannot be regenerated and the patient falls into heart failure. When this condition is reached, the only treatment available is to install a left ventricular assist device or, ultimately, to undergo a heart transplant.
In this context, research is being conducted into cell transplantation into the heart as a new treatment for heart failure. To date, the use of fetal cardiomyocytes, skeletal myoblasts, ES cells, and bone marrow-derived cells has been reported in animal experiments.
このうち骨格筋芽細胞は、骨格筋組織中に存在し、筋組織が障害を受けた際に活性化され、増殖、融合することにより骨格筋組織を再生する。骨格筋芽細胞は、心筋と構造、機能などに類似する部分が多く、増殖して梗塞巣を修復できない心筋細胞の代わりに当該病巣を物理的に補填し、心臓のポンプ機能を改善できるのではないか、という考え方から心疾患への適応が期待されてきた。一方、近年ではその有効性にも関わらず移植細胞の生着率が低いことから、移植細胞の産生する液性因子が心筋組織に作用し、細胞死の抑制、血管新生などの作用によりその有効性を示すのではないかとも考えられている。また、骨格筋芽細胞を利用した細胞移植の場合、患者自身の細胞を用いることで免疫適合性の問題を回避することが可能であるという利点があり、海外では臨床試験も行われている。
しかし、移植細胞を細胞懸濁液の状態で組織へと投与した場合には、移植細胞の注入効率が悪いこと、レシピエント組織への穿刺による障害、広範囲な組織修復が困難である等の問題点が指摘されており、これを克服すべくスキャフォールドを利用した細胞構築物や細胞をシート状に形成した細胞シートが開発されてきた。
Of these, skeletal myoblasts are present in skeletal muscle tissue, and when muscle tissue is damaged, they are activated and proliferate and fuse to regenerate skeletal muscle tissue. Skeletal myoblasts have many similarities in structure and function to myocardium, and it has been expected that they can be used to treat heart disease, as they can physically compensate for the lesion and improve the pumping function of the heart, instead of myocardial cells that cannot proliferate to repair the infarct. On the other hand, in recent years, despite their effectiveness, the engraftment rate of transplanted cells has been low, so it is thought that their effectiveness may be demonstrated by the humoral factors produced by the transplanted cells acting on the myocardial tissue, suppressing cell death, and causing angiogenesis. In addition, cell transplantation using skeletal myoblasts has the advantage of being able to avoid the problem of immune compatibility by using the patient's own cells, and clinical trials are being conducted overseas.
However, when transplant cells are administered to tissues in the form of a cell suspension, problems have been pointed out, such as poor injection efficiency of the transplant cells, damage caused by puncturing the recipient tissue, and difficulty in repairing tissue over a wide area. To overcome these problems, cell structures using scaffolds and cell sheets made of cells formed into a sheet-like form have been developed.
骨格筋芽細胞についても、適切な培養液中で一定期間増殖させることにより細胞シートの形成が可能であることが知られている（特許文献1）。同文献において、骨格筋芽細胞シートは、細胞を約９×１０４細胞／ｃｍ２の密度で播種し、成長因子等を含む培養液中で十分な期間増殖させることにより形成している。しかしながら、このような製造方法においては、培養液中に含まれる成長因子、ステロイド剤、異種血清等の添加因子が製造物に残存する可能性があるという安全性の問題があった。また、かかる従来の製造方法においては、形成される細胞シートが物理的強度に乏しく、洗浄操作や移植手術、輸送の際の扱いが困難であるという問題点があった。さらに、近年では治療法としての細胞移植の作用メカニズムとして、移植細胞から産生される液性因子の働きが注目されているが、移植細胞からは治療の有効性に関わる因子の他、炎症性サイトカイン等、レシピエントに対して不利益な効果をもたらす因子も産生される可能性があるため、細胞シートの臨床応用にむけては、血管新生、細胞死の抑制等、有効性に関わる因子を多く産生し、炎症性サイトカイン産生の抑制された細胞シートを得ることが望ましい。したがって、上記のような従来技術の問題点を有しない、強度、安全性および有効性の高い細胞シートの製造が求められていた。 It is also known that cell sheets can be formed from skeletal myoblasts by growing them in a suitable culture medium for a certain period of time (Patent Document 1). In this document, skeletal myoblast cell sheets are formed by seeding cells at a density of about 9 x 104 cells/ cm2 and growing them in a culture medium containing growth factors and the like for a sufficient period of time. However, in such a production method, there is a safety issue that additive factors such as growth factors, steroids, and xenogeneic serum contained in the culture medium may remain in the product. In addition, in such a conventional production method, there is a problem that the formed cell sheet has poor physical strength and is difficult to handle during washing operations, transplantation surgery, and transportation. Furthermore, in recent years, the function of humoral factors produced by transplanted cells has been attracting attention as the mechanism of action of cell transplantation as a treatment method, but in addition to factors related to the effectiveness of treatment, transplanted cells may also produce factors such as inflammatory cytokines that have adverse effects on the recipient. Therefore, for the clinical application of cell sheets, it is desirable to obtain cell sheets that produce a large number of factors related to effectiveness, such as angiogenesis and inhibition of cell death, and suppress the production of inflammatory cytokines. Therefore, there has been a demand for the production of cell sheets that are free from the above-mentioned problems of the conventional techniques and that have high strength, safety and effectiveness.
本発明は、従来技術の問題点を有しない、強度、安全性および有効性に優れたシート状細胞培養物の製造を目的とする。 The present invention aims to produce a sheet-shaped cell culture that is strong, safe, and effective and does not have the problems of the prior art.
本発明者らは、上記課題を解決すべく鋭意研究を行う中で、骨格筋芽細胞を１．０×１０６個／ｃｍ２を超える密度で播種した場合、播種された細胞が完全にシートを形成する以前に剥離が生じ、十分な強度をもつシート状細胞培養物を形成することができなかったが、前処理として培養基材に血清を被覆させた後に高密度の細胞を播種したところ、自然に剥離することなくシート状細胞培養物を形成することが可能であることを見出した。また、より低密度の播種密度３．５×１０５個／ｃｍ２の場合において、血清被覆処理をした培養皿を使用することにより、かかる処理を行っていない培養皿を使用した場合に比べてシートを構成する細胞数が増加、すなわち、細胞回収率が上昇し、シートの強度も高まることを見出した。そして、さらに研究を続けたところ、多核化していない骨格筋芽細胞のシート状細胞培養物からは、分化が進み多核化した骨格筋芽細胞のシート状細胞培養物と比較して血管新生等の有効性に関わる作用を有する因子の産生が多い一方で、炎症性サイトカインの産生が低いこと、および、上記製造方法で作製されたシート状細胞培養物について分化の程度を評価したところ、分化の進行がみられないことを見出し、本発明を完成させた。 In the course of intensive research to solve the above problems, the present inventors have found that when skeletal myoblasts are seeded at a density exceeding 1.0x106 cells/ cm2 , detachment occurs before the seeded cells completely form a sheet, making it impossible to form a sheet-shaped cell culture with sufficient strength, but when a culture substrate is coated with serum as a pretreatment and then a high density of cells is seeded, a sheet-shaped cell culture can be formed without spontaneous detachment. Furthermore, in the case of a lower seeding density of 3.5x105 cells/ cm2 , the use of a serum-coated culture dish increases the number of cells constituting the sheet, i.e., increases the cell recovery rate and increases the strength of the sheet, compared to the use of a culture dish that has not been subjected to such treatment. As a result of further research, the researchers found that sheet-shaped cell cultures of non-multinucleated skeletal myoblasts produced greater amounts of factors that have effects related to the efficacy of angiogenesis, etc., compared to sheet-shaped cell cultures of differentiated, multinucleated skeletal myoblasts, but produced less inflammatory cytokines, and that when the degree of differentiation of the sheet-shaped cell cultures produced by the above-mentioned manufacturing method was evaluated, no progression of differentiation was observed, thereby completing the present invention.
したがって、本発明は以下の（１）～（１０）に示されるものである。
（１）血清で被覆された培養基材上に、実質的に増殖することなくシート状細胞培養物を形成し得る密度の細胞を播種する工程を含む、シート状細胞培養物の製造方法。
（２）細胞の密度が３．５×１０５以上、３．４×１０６個／ｃｍ２未満である、上記（１）に記載の製造方法。
（３）シート状細胞培養物を培養基材から単離する工程をさらに含む、上記（１）または（２）に記載の製造方法。
（４）単離したシート状細胞培養物を洗浄する工程をさらに含む、上記（１）～（３）のいずれかに記載の製造方法。
（５）シート状細胞培養物が、筋管への分化が抑制された骨格筋芽細胞を含む、上記（１）～（４）のいずれかに記載の製造方法。
（６）上記（１）～（５）のいずれかに記載の方法により製造された、シート状細胞培養物。
（７）洗浄操作に対して十分な物理的強度を有する、上記（６）に記載のシート状細胞培養物。
（８）移植操作に耐え得る物理的強度を有する、上記（６）または（７）に記載のシート状細胞培養物。
（９）疾病または傷病の治療に用いる、上記（６）～（８）のいずれかに記載のシート状細胞培養物。
（１０）製造由来不純物を実質的に含まない、上記（６）～（９）のいずれかに記載のシート状細胞培養物。
Therefore, the present invention is as shown in the following (1) to (10).
(1) A method for producing a sheet-shaped cell culture, comprising the step of seeding cells on a serum-coated culture substrate at a density sufficient to form a sheet-shaped cell culture without substantial proliferation.
(2) The manufacturing method described in (1) above, wherein the cell density is 3.5 x 105 or more and less than 3.4 x 106 cells/ cm2 .
(3) The method according to (1) or (2) above, further comprising a step of isolating the sheet-shaped cell culture from the culture substrate.
(4) The method according to any one of (1) to (3) above, further comprising a step of washing the isolated sheet-shaped cell culture.
(5) The method according to any one of (1) to (4) above, wherein the sheet-shaped cell culture contains skeletal myoblasts whose differentiation into myotubes is inhibited.
(6) A sheet-shaped cell culture produced by the method according to any one of (1) to (5) above.
(7) The sheet-shaped cell culture according to (6) above, which has sufficient physical strength to withstand a washing operation.
(8) The sheet-shaped cell culture according to (6) or (7) above, which has a physical strength sufficient to withstand transplantation procedures.
(9) The sheet-shaped cell culture according to any one of (6) to (8) above, for use in treating a disease or injury.
(10) The sheet-shaped cell culture according to any one of (6) to (9) above, which is substantially free of impurities derived from production.
本発明の製造方法により、浸漬撹拌などの洗浄操作や、取出し、保持、移送などの移植操作に耐え得る十分な物理的強度を有するシート状細胞培養物が得られるため、従来の製法で得られた細胞シートよりもより容易かつ確実に製造・移植操作を行うことが可能となる。また、本発明の製造方法により、高い細胞回収率でシート状細胞培養物を得ることができるため、使用する細胞の有効利用が可能となり、コストの削減などに寄与する。さらに、本発明の製造方法により得られたシート状細胞培養物は、血管新生等の有効性に関わる作用を有する因子の産生が多い一方で、炎症性サイトカインの産生が低いため、治療上の有効性も、レシピエントに対する安全性も極めて高く、臨床的に極めて有用である。このため、ヒト医療および獣医療において多大な貢献が期待できる。 The manufacturing method of the present invention can obtain a sheet-shaped cell culture that has sufficient physical strength to withstand washing operations such as immersion and agitation, and transplantation operations such as removal, holding, and transportation, making it possible to carry out manufacturing and transplantation operations more easily and reliably than cell sheets obtained by conventional manufacturing methods. In addition, the manufacturing method of the present invention can obtain a sheet-shaped cell culture with a high cell recovery rate, allowing for effective use of the cells used and contributing to cost reduction, etc. Furthermore, the sheet-shaped cell culture obtained by the manufacturing method of the present invention produces a large amount of factors that have effects related to the effectiveness of angiogenesis, etc., while producing a low amount of inflammatory cytokines, so that it is extremely effective in treatment and safe for the recipient, and is extremely useful clinically. For this reason, it is expected to make a significant contribution to human and veterinary medicine.
本発明は、血清で被覆された培養基材上に、実質的に増殖することなくシート状細胞培養物を形成し得る密度の細胞を播種する工程を含む、シート状細胞培養物の製造方法に関する。
本発明において、「培養基材」は、細胞がその上でシート状細胞培養物を形成し得るものであれば特に限定されず、例えば、種々の材質の容器、容器中の固形もしくは半固形の表面などを含む。容器は、培養液などの液体を透過させない構造・材料が好ましい。かかる材料としては、限定することなく、例えば、ポリエチレン、ポリプロピレン、テフロン（登録商標）、ポリエチレンテレフタレート、ポリメチルメタクリレート、ナイロン６，６、ポリビニルアルコール、セルロース、シリコン、ポリスチレン、ガラス、ポリアクリルアミド、ポリジメチルアクリルアミド、金属（例えば、鉄、ステンレス、アルミニウム、銅、真鍮）等が挙げられる。また、容器は、少なくとも１つの平坦な面を有することが好ましい。かかる容器の例としては、限定することなく、例えば、細胞培養皿、細胞培養ボトルなどが挙げられる。また、容器は、その内部に固形もしくは半固形の表面を有してもよい。固形の表面としては、上記のごとき種々の材料のプレートや容器などが、半固形の表面としては、ゲル、軟質のポリマーマトリクスなどが挙げられる。
The present invention relates to a method for producing a sheet-shaped cell culture, which comprises a step of seeding cells on a serum-coated culture substrate at a density that allows the formation of a sheet-shaped cell culture without substantial proliferation.
In the present invention, the "culture substrate" is not particularly limited as long as the cells can form a sheet-shaped cell culture thereon, and includes, for example, containers made of various materials, solid or semi-solid surfaces in the containers, and the like. The container is preferably made of a structure or material that is impermeable to liquids such as culture fluid. Examples of such materials include, but are not limited to, polyethylene, polypropylene, Teflon (registered trademark), polyethylene terephthalate, polymethyl methacrylate, nylon 6,6, polyvinyl alcohol, cellulose, silicon, polystyrene, glass, polyacrylamide, polydimethylacrylamide, metals (e.g., iron, stainless steel, aluminum, copper, brass), and the like. In addition, the container preferably has at least one flat surface. Examples of such containers include, but are not limited to, cell culture dishes, cell culture bottles, and the like. In addition, the container may have a solid or semi-solid surface inside. Examples of solid surfaces include plates and containers made of various materials such as those described above, and examples of semi-solid surfaces include gels and soft polymer matrices.
培養基材は、刺激、例えば、温度や光に応答して物性が変化する材料で表面が被覆されていてもよい。かかる材料としては、限定されずに、例えば、（メタ）アクリルアミド化合物、Ｎ－アルキル置換（メタ）アクリルアミド誘導体（例えば、Ｎ－エチルアクリルアミド、Ｎ－ｎ－プロピルアクリルアミド、Ｎ－ｎ－プロピルメタクリルアミド、Ｎ－イソプロピルアクリルアミド、Ｎ－イソプロピルメタクリルアミド、Ｎ－シクロプロピルアクリルアミド、Ｎ－シクロプロピルメタクリルアミド、Ｎ－エトキシエチルアクリルアミド、Ｎ－エトキシエチルメタクリルアミド、Ｎ－テトラヒドロフルフリルアクリルアミド、Ｎ－テトラヒドロフルフリルメタクリルアミド等）、Ｎ，Ｎ－ジアルキル置換（メタ）アクリルアミド誘導体（例えば、Ｎ，Ｎ－ジメチル（メタ）アクリルアミド、Ｎ，Ｎ－エチルメチルアクリルアミド、Ｎ，Ｎ－ジエチルアクリルアミド等）、環状基を有する（メタ）アクリルアミド誘導体（例えば、１－（１－オキソ－２－プロペニル）－ピロリジン、１－（１－オキソ－２－プロペニル）－ピペリジン、４－（１－オキソ－２－プロペニル）－モルホリン、１－（１－オキソ－２－メチル－２－プロペニル）－ピロリジン、１－（１－オキソ－２－メチル－２－プロペニル）－ピペリジン、４－（１－オキソ－２－メチル－２－プロペニル）－モルホリン等）、またはビニルエーテル誘導体（例えば、メチルビニルエーテル）のホモポリマーまたはコポリマーからなる温度応答性材料、アゾベンゼン基を有する光吸収性高分子、トリフェニルメタンロイコハイドロオキシドのビニル誘導体とアクリルアミド系単量体との共重合体、および、スピロベンゾピランを含むＮ－イソプロピルアクリルアミドゲル等の光応答性材料などの公知のものを用いることができる（例えば、特開平2-211865、特開2003-33177参照）。これらの材料に所定の刺激を与えることによりその物性、例えば、親水性や疎水性を変化させ、同材料上に付着した細胞培養物の剥離を促進することができる。
上記培養基材は、種々の形状であってもよいが、平坦であることが好ましい。また、その面積は特に限定されないが、典型的には、１～２００ｃｍ２、好ましくは２～１００ｃｍ２、より好ましくは３～５０ｃｍ２である。
The surface of the culture substrate may be coated with a material whose physical properties change in response to a stimulus, for example, temperature or light. Examples of such materials include, but are not limited to, (meth)acrylamide compounds, N-alkyl-substituted (meth)acrylamide derivatives (e.g., N-ethylacrylamide, N-n-propylacrylamide, N-n-propylmethacrylamide, N-isopropylacrylamide, N-isopropylmethacrylamide, N-cyclopropylacrylamide, N-cyclopropylmethacrylamide, N-ethoxyethylacrylamide, N-ethoxyethylmethacrylamide, N-tetrahydrofurfurylacrylamide, N-tetrahydrofurfurylmethacrylamide, etc.), N,N-dialkyl-substituted (meth)acrylamide derivatives (e.g., N,N-dimethyl(meth)acrylamide, N,N-ethylmethylacrylamide, N,N-diethylacrylamide, etc.), (meth)acrylamide derivatives having a cyclic group (e.g., 1-(1 Examples of materials that can be used include temperature-responsive materials made of homopolymers or copolymers of 1-(1-oxo-2-propenyl)-pyrrolidine, 1-(1-oxo-2-propenyl)-piperidine, 4-(1-oxo-2-propenyl)-morpholine, 1-(1-oxo-2-methyl-2-propenyl)-pyrrolidine, 1-(1-oxo-2-methyl-2-propenyl)-piperidine, 4-(1-oxo-2-methyl-2-propenyl)-morpholine, or vinyl ether derivatives (e.g., methyl vinyl ether); light-absorbing polymers having an azobenzene group; copolymers of vinyl derivatives of triphenylmethane leucohydroxide and acrylamide monomers; and light-responsive materials such as N-isopropylacrylamide gel containing spirobenzopyran (e.g., see JP-A-2-211865 and JP-A-2003-33177). By applying a specific stimulus to these materials, their physical properties, such as hydrophilicity or hydrophobicity, can be changed, thereby facilitating the detachment of cell cultures attached to the materials.
The culture substrate may have various shapes, but is preferably flat. The area of the substrate is not particularly limited, but is typically 1 to 200 cm 2 , preferably 2 to 100 cm 2 , and more preferably 3 to 50 cm 2 .
本発明において、培養基材は血清でコート（被覆またはコーティング）されている。「血清でコートされている」とは、培養基材の表面に血清成分が付着している状態を意味する。かかる状態は、限定されずに、例えば、培養基材を血清と共にインキュベートすることにより得ることができる。インキュベートとは、血清を培養基材に接触させることを含む。血清としては、異種血清および同種血清を用いることができる。異種血清は、細胞培養物を移植する場合、レシピエントとは異なる種の生物に由来する血清を意味する。例えば、レシピエントがヒトである場合、ウシやウマに由来する血清、例えば、ウシ胎仔血清（ＦＢＳ、ＦＣＳ）、仔ウシ血清（ＣＳ）、ウマ血清（ＨＳ）などが異種血清に該当する。また、「同種血清」は、レシピエントと同一の種の生物に由来する血清を意味する。例えば、レシピエントがヒトである場合、ヒト血清が同種血清に該当する。同種血清は、自己血清、すなわち、レシピエントに由来する血清を含む。
培養基材をコートするための血清は、市販されているか、または、所望の生物から採取した血液から定法により調製することができる。具体的には、例えば、採取した血液を室温で２０～６０分程度放置して凝固させ、これを１０００～１２００×ｇ程度で遠心分離し、上清を採取する方法などが挙げられる。
In the present invention, the culture substrate is coated with serum. "Coated with serum" means a state in which serum components are attached to the surface of the culture substrate. Such a state is not limited, and can be obtained, for example, by incubating the culture substrate with serum. Incubation includes contacting serum with the culture substrate. As the serum, xenogeneic serum and allogeneic serum can be used. When transplanting a cell culture, xenogeneic serum means serum derived from an organism of a different species from the recipient. For example, when the recipient is a human, serum derived from a cow or horse, such as fetal bovine serum (FBS, FCS), calf serum (CS), and horse serum (HS), corresponds to xenogeneic serum. In addition, "allogeneic serum" means serum derived from an organism of the same species as the recipient. For example, when the recipient is a human, human serum corresponds to allogeneic serum. Allogeneic serum includes autologous serum, that is, serum derived from the recipient.
Serum for coating the culture substrate is commercially available or can be prepared by a standard method from blood collected from a desired organism. Specifically, for example, collected blood is left at room temperature for about 20 to 60 minutes to coagulate, and then centrifuged at about 1000 to 1200×g to collect the supernatant.
培養基材上でインキュベートする場合、血清は原液で用いても、希釈して用いてもよい。希釈は、任意の媒体、例えば、限定することなく、水、生理食塩水、種々の緩衝液（例えば、ＰＢＳ、ＨＢＳなど）、種々の液体培地（例えば、ＤＭＥＭ、ＭＥＭ、Ｆ１２、ＤＭＥ、ＲＰＭＩ１６４０、ＭＣＤＢ（ＭＣＤＢ１０２、１０４、１０７、１３１、１５３、１９９など）、Ｌ１５、ＳｋＢＭ、ＲＩＴＣ８０－７、ＤＭＥＭ／Ｆ１２など）等で行うことができる。希釈濃度は、血清成分が培養基材上に付着することができれば特に限定されず、例えば、０．５～９０％（ｖ／ｖ）、好ましくは１～６０％（ｖ／ｖ）、より好ましくは５～４０％（ｖ／ｖ）である。
インキュベート時間も、血清成分が培養基材上に付着することができれば特に限定されず、例えば、１～７２時間、好ましくは４～４８時間、より好ましくは５～２４時間、さらに好ましくは６～１２時間である。インキュベート温度も、血清成分が培養基材上に付着することができれば特に限定されず、例えば、０～６０℃、好ましくは４～４５℃、より好ましくは室温～４０℃である。
When incubating on a culture substrate, serum may be used in its original form or diluted. Dilution can be performed with any medium, for example, without limitation, water, physiological saline, various buffer solutions (e.g., PBS, HBS, etc.), various liquid media (e.g., DMEM, MEM, F12, DME, RPMI1640, MCDB (MCDB102, 104, 107, 131, 153, 199, etc.), L15, SkBM, RITC80-7, DMEM/F12, etc.). The dilution concentration is not particularly limited as long as the serum components can adhere to the culture substrate, and is, for example, 0.5 to 90% (v/v), preferably 1 to 60% (v/v), more preferably 5 to 40% (v/v).
The incubation time is also not particularly limited as long as the serum components can adhere to the culture substrate, and is, for example, 1 to 72 hours, preferably 4 to 48 hours, more preferably 5 to 24 hours, and even more preferably 6 to 12 hours. The incubation temperature is also not particularly limited as long as the serum components can adhere to the culture substrate, and is, for example, 0 to 60°C, preferably 4 to 45°C, and more preferably room temperature to 40°C.
インキュベート後に血清を廃棄してもよい。血清の廃棄手法としては、ピペットなどによる吸引や、デカンテーションなどの慣用の液体廃棄手法を用いることができる。本発明の一態様においては、血清廃棄後に、培養基材を無血清洗浄液で洗浄してもよい。無血清洗浄液としては、血清を含まず、培養基材に付着した血清成分に悪影響を与えない液体媒体であれば特に限定されず、例えば、限定することなく、水、生理食塩水、種々の緩衝液（例えば、ＰＢＳ、ＨＢＳなど）、種々の液体培地（例えば、ＤＭＥＭ、ＭＥＭ、Ｆ１２、ＤＭＥ、ＲＰＭＩ１６４０、ＭＣＤＢ（ＭＣＤＢ１０２、１０４、１０７、１３１、１５３、１９９など）、Ｌ１５、ＳｋＢＭ、ＲＩＴＣ８０－７、ＤＭＥＭ／Ｆ１２など）等で行うことができる。洗浄手法としては、慣用の培養基材洗浄手法、例えば、限定することなく、培養基材上に無血清洗浄液を加えて所定時間（例えば、５～６０秒間）撹拌後、廃棄する手法などを用いることができる。 After incubation, the serum may be discarded. As a method for discarding the serum, a conventional liquid discarding method such as suction with a pipette or decantation can be used. In one aspect of the present invention, after discarding the serum, the culture substrate may be washed with a serum-free washing solution. The serum-free washing solution is not particularly limited as long as it is a liquid medium that does not contain serum and does not adversely affect the serum components attached to the culture substrate, and can be, for example, water, physiological saline, various buffer solutions (e.g., PBS, HBS, etc.), various liquid media (e.g., DMEM, MEM, F12, DME, RPMI1640, MCDB (MCDB102, 104, 107, 131, 153, 199, etc.), L15, SkBM, RITC80-7, DMEM/F12, etc.), etc. As a washing method, a conventional culture substrate washing method can be used, for example, a method in which a serum-free washing solution is added to the culture substrate, stirred for a predetermined time (e.g., 5 to 60 seconds), and then discarded.
本発明において、培養基材を、成長因子でコートしてもよい。ここで、「成長因子」は、細胞の増殖を、それがない場合に比べて促進する任意の物質を意味し、例えば、上皮細胞成長因子（ＥＧＦ）、血管内皮成長因子（ＶＥＧＦ）、線維芽細胞成長因子（ＦＧＦ）などを含む。成長因子による培養基材のコート手法、廃棄手法および洗浄手法は、インキュベーション時の希釈濃度が、例えば、０．０００１μｇ／ｍＬ～１μｇ／ｍＬ、好ましくは０．０００５μｇ／ｍＬ～０．０５μｇ／ｍＬ、より好ましくは０．００１μｇ／ｍＬ～０．０１μｇ／ｍＬである以外は、基本的に血清と同じである。 In the present invention, the culture substrate may be coated with a growth factor. Here, "growth factor" means any substance that promotes cell proliferation compared to the absence of the growth factor, and includes, for example, epidermal growth factor (EGF), vascular endothelial growth factor (VEGF), fibroblast growth factor (FGF), etc. The method of coating, discarding, and washing the culture substrate with the growth factor is basically the same as that of serum, except that the dilution concentration during incubation is, for example, 0.0001 μg/mL to 1 μg/mL, preferably 0.0005 μg/mL to 0.05 μg/mL, and more preferably 0.001 μg/mL to 0.01 μg/mL.
本発明において、培養基材を、ステロイド剤でコートしてもよい。ここで「ステロイド剤成分」は、ステロイド核を有する化合物のうち、生体に、副腎皮質機能不全、クッシング症候群などの悪影響を及ぼし得るものをいう。かかる化合物としては、限定されずに、例えば、コルチゾール、プレドニゾロン、トリアムシノロン、デキサメタゾン、ベタメタゾン等が含まれる。ステロイド剤による培養基材のコート手法、廃棄手法および洗浄手法は、インキュベーション時の希釈濃度が、デキサメタゾンとして、例えば、０．１μｇ／ｍＬ～１００μｇ／ｍＬ、好ましくは０．４μｇ／ｍＬ～４０μｇ／ｍＬ、より好ましくは１μｇ／ｍＬ～１０μｇ／ｍＬである以外は、基本的に血清と同じである。 In the present invention, the culture substrate may be coated with a steroid agent. Here, the term "steroid agent component" refers to a compound having a steroid nucleus that may have adverse effects on the living body, such as adrenal insufficiency and Cushing's syndrome. Such compounds include, but are not limited to, for example, cortisol, prednisolone, triamcinolone, dexamethasone, betamethasone, etc. The method of coating the culture substrate with the steroid agent, the method of disposal, and the method of washing are basically the same as those for serum, except that the dilution concentration during incubation is, for example, 0.1 μg/mL to 100 μg/mL, preferably 0.4 μg/mL to 40 μg/mL, and more preferably 1 μg/mL to 10 μg/mL, as dexamethasone.
培養基材は、血清、成長因子およびステロイド剤のいずれか１つでコートしても、これらの任意の組合わせ、すなわち、血清と成長因子、血清とステロイド剤、または血清と成長因子とステロイド剤の組合わせでコートしてもよい。複数の成分でコートする場合、これらの成分を混合して同時にコートしてもよいし、別々の工程でコートしてもよい。 The culture substrate may be coated with serum, growth factors, and steroids, or any combination of these, i.e., serum and growth factors, serum and steroids, or serum, growth factors, and steroids. When coated with multiple components, these components may be mixed and coated simultaneously or in separate steps.
培養基材は、血清等でコートした後直ちに細胞を播種してもよいし、コートした後に保存しておき、その後細胞を播種することもできる。コートした基材は、例えば４℃以下、好ましくは－２０℃以下、より好ましくは－８０℃以下に保つことにより長期間保存することができる。 The culture substrate may be coated with serum or the like and then seeded with cells immediately, or may be stored after coating and then seeded with cells. The coated substrate can be stored for a long period of time by keeping it at a temperature of, for example, 4°C or lower, preferably -20°C or lower, and more preferably -80°C or lower.
本発明の製造方法において、細胞は、実質的に増殖することなくシート状細胞培養物を形成し得る密度で播種する。「実質的に増殖することなくシート状細胞培養物を形成し得る密度」とは、成長因子を実質的に含まない非増殖系の培養液で培養した場合に、シート状細胞培養物を形成することができる細胞密度を意味する。例えば、骨格筋芽細胞の場合、成長因子を含む培養液を用いる従来法では、シート状細胞培養物を形成するために、約６，５００個／ｃｍ２の密度の細胞をプレートに播種していたが（例えば、特許文献１参照）、かかる密度の細胞を、成長因子を含まない培養液で培養してもシート状の細胞培養物を形成することはできない。したがって、本発明の製造方法における播種密度は、成長因子を含む培養液を用いる従来法におけるものよりも高いものである。このため、本明細書中では、かかる播種密度を、単に「高密度」と記すこともある。かかる密度は、具体的には、例えば、骨格筋芽細胞について典型的には３００，０００個／ｃｍ２以上である。播種密度の上限は、細胞培養物の形成が損なわれず、細胞が分化に移行しなければ特に制限されないが、骨格筋芽細胞については、３．４×１０６個／ｃｍ２未満である。 In the production method of the present invention, the cells are seeded at a density at which a sheet-shaped cell culture can be formed without substantial proliferation. The term "density at which a sheet-shaped cell culture can be formed without substantial proliferation" refers to a cell density at which a sheet-shaped cell culture can be formed when cultured in a non-proliferation culture medium that does not substantially contain growth factors. For example, in the case of skeletal myoblasts, in a conventional method using a culture medium containing growth factors, cells are seeded on a plate at a density of about 6,500 cells/ cm2 to form a sheet-shaped cell culture (see, for example, Patent Document 1), but even if cells at such a density are cultured in a culture medium that does not contain growth factors, a sheet-shaped cell culture cannot be formed. Therefore, the seeding density in the production method of the present invention is higher than that in the conventional method using a culture medium containing growth factors. For this reason, in the present specification, such a seeding density may be simply referred to as "high density". Specifically, such a density is typically 300,000 cells/ cm2 or more for skeletal myoblasts, for example. The upper limit of the seeding density is not particularly limited as long as the formation of the cell culture is not impaired and the cells do not undergo differentiation, but for skeletal myoblasts, it is less than 3.4 x 106 cells/ cm2 .
したがって、本発明の製造方法における骨格筋芽細胞の播種密度は、ある態様では３．０×１０５～３．４×１０６個／ｃｍ２、別の態様では３．５×１０５～３．４×１０６個／ｃｍ２、さらに別の態様では１．０×１０６～３．４×１０６個／ｃｍ２、さらに別の態様では３．０×１０５～１．７×１０６個／ｃｍ２、別の態様では３．５×１０５～１．７×１０６個／ｃｍ２、さらに別の態様では１．０×１０６～１．７×１０６個／ｃｍ２である。上記範囲は、上限が３．４×１０６個／ｃｍ２未満である限り、上限および下限の両方、または、そのいずれか一方を含んでもよい。したがって、本発明の製造方法における骨格筋芽細胞の播種密度は、例えば、３．０×１０５個／ｃｍ２以上３．４×１０６個／ｃｍ２未満（下限を含み、上限は含まない）、３．５×１０５個／ｃｍ２以上３．４×１０６個／ｃｍ２未満（下限を含み、上限は含まない）、１．０×１０６個／ｃｍ２以上３．４×１０６個／ｃｍ２未満（下限を含み、上限は含まない）、１．０×１０６個／ｃｍ２超３．４×１０６個／ｃｍ２未満（下限も上限も含まない）、１．０×１０６個／ｃｍ２超１．７×１０６個／ｃｍ２以下（下限は含まないが、上限は含む）であってもよい。当業者であれば、骨格筋芽細胞以外の細胞について、本発明に適した細胞密度を、本明細書の教示に従い、実験により適宜決定することができる。 Thus, the seeding density of skeletal myoblasts in the production method of the present invention is 3.0×10 5 to 3.4×10 6 cells/cm 2 in one embodiment, 3.5×10 5 to 3.4×10 6 cells/cm 2 in another embodiment, 1.0×10 6 to 3.4×10 6 cells/cm 2 in yet another embodiment, 3.0×10 5 to 1.7×10 6 cells/cm 2 in yet another embodiment, 3.5×10 5 to 1.7×10 6 cells/cm 2 in another embodiment, and 1.0×10 6 to 1.7×10 6 cells/cm 2 in yet another embodiment. The above range may include both the upper and lower limits, or either one of them, as long as the upper limit is less than 3.4×10 6 cells/cm 2 . Therefore, the seeding density of skeletal myoblasts in the production method of the present invention may be, for example, 3.0 x 105 cells/cm2 or more and less than 3.4 x 106 cells/ cm2 (including the lower limit and excluding the upper limit), 3.5 x 105 cells/ cm2 or more and less than 3.4 x 106 cells/ cm2 (including the lower limit and excluding the upper limit), 1.0 x 106 cells/ cm2 or more and less than 3.4 x 106 cells/ cm2 (including the lower limit and excluding the upper limit), more than 1.0 x 106 cells/ cm2 and less than 3.4 x 106 cells/ cm2 (including neither the lower limit nor the upper limit), more than 1.0 x 106 cells/ cm2 and 1.7 x 106 cells/ cm2 or less (including the upper limit but not including the lower limit). A person skilled in the art can appropriately determine the cell density suitable for the present invention for cells other than skeletal myoblasts by experiment according to the teachings of this specification.
培養期間中、細胞は増殖してもしなくてもよいが、増殖するとしても、細胞の性状が変化する程には増殖しない。例えば、骨格筋芽細胞はコンフルエントになると分化を開始するが、本発明においては、骨格筋芽細胞は、細胞培養物は形成するが、分化に移行しない密度で播種される。本発明の好ましい態様において、細胞は計測誤差の範囲を超えて増殖しない。細胞が増殖したか否かは、例えば、播種時の細胞数と、細胞培養物形成後の細胞数とを比較することにより評価することができる。本態様において、細胞培養物形成後の細胞数は、典型的には播種時の細胞数の３００％以下、好ましくは２００％以下、より好ましくは１５０％以下、さらに好ましくは１２５％以下、特に好ましくは１００％以下である。 During the culture period, the cells may or may not proliferate, but even if they do, they do not proliferate to such an extent that the properties of the cells change. For example, skeletal myoblasts begin to differentiate when they become confluent, but in the present invention, the skeletal myoblasts are seeded at a density that forms a cell culture but does not transition to differentiation. In a preferred embodiment of the present invention, the cells do not proliferate beyond the range of measurement error. Whether the cells have proliferated or not can be evaluated, for example, by comparing the number of cells at the time of seeding with the number of cells after the formation of the cell culture. In this embodiment, the number of cells after the formation of the cell culture is typically 300% or less of the number of cells at the time of seeding, preferably 200% or less, more preferably 150% or less, even more preferably 125% or less, and particularly preferably 100% or less.
本発明において、細胞の培養は、対象となる細胞がシート状の細胞培養物を形成するのに適した条件で行われる。
本発明において、「シート状細胞培養物」は、細胞が互いに連結してシート状になったものをいい、典型的には１つの細胞層からなるものであるが、２以上の細胞層から構成されるものも含む。細胞同士は、直接および／または介在物質を介して、互いに連結していてもよい。介在物質としては、細胞同士を少なくとも機械的に連結し得る物質であれば特に限定されないが、例えば、細胞外マトリックスなどが挙げられる。介在物質は、好ましくは細胞由来のもの、特に、細胞培養物を構成する細胞に由来するものである。細胞は少なくとも機械的に連結されるが、さらに機能的、例えば、化学的、電気的に連結されてもよい。
In the present invention, the cells are cultured under conditions suitable for the cells to form a sheet-like cell culture.
In the present invention, the term "sheet-shaped cell culture" refers to a sheet-like structure in which cells are linked to each other, typically consisting of one cell layer, but also including a sheet consisting of two or more cell layers. The cells may be linked to each other directly and/or via an intervening substance. The intervening substance is not particularly limited as long as it is a substance that can at least mechanically link the cells to each other, and examples of such substances include extracellular matrix. The intervening substance is preferably derived from cells, particularly from the cells that constitute the cell culture. The cells are at least mechanically linked, but may also be functionally linked, for example chemically or electrically.
本発明のシート状細胞培養物は、好ましくはスキャフォールド（支持体）を含まない。スキャフォールドは、その表面上および／またはその内部に細胞を付着させ、細胞培養物の物理的一体性を維持するために当該技術分野において用いられることがあり、例えば、ポリビニリデンジフルオリド（ＰＶＤＦ）製の膜等が知られているが、本発明の細胞培養物は、かかるスキャフォールドがなくともその物理的一体性を維持することができる。また、本発明の細胞培養物は、好ましくは、細胞培養物を構成する細胞由来の物質のみからなり、それら以外の物質を含まない。 The sheet-shaped cell culture of the present invention preferably does not include a scaffold (support). Scaffolds are sometimes used in the art to attach cells to their surface and/or inside and maintain the physical integrity of the cell culture; for example, membranes made of polyvinylidene difluoride (PVDF) are known, but the cell culture of the present invention can maintain its physical integrity even without such a scaffold. In addition, the cell culture of the present invention preferably consists only of substances derived from the cells that constitute the cell culture, and does not include any other substances.
本発明の一態様において、細胞の培養は、所定の期間内、好ましくは、細胞が分化に移行しない期間内に行われる。したがって、この態様において、細胞は、培養期間中、未分化の状態に維持される。細胞の分化への移行は、当業者に知られた任意の方法で評価することができる。例えば、骨格筋芽細胞の場合は、ＭＨＣの発現、クレアチンキナーゼ（ＣＫ）活性、細胞の多核化、筋管の形成などを分化の指標とすることができる。本発明の好ましい態様において、培養期間は４８時間以内、より好ましくは４０時間以内、さらに好ましくは２４時間以内である。 In one embodiment of the present invention, the cells are cultured for a predetermined period of time, preferably within a period during which the cells do not undergo differentiation. Thus, in this embodiment, the cells are maintained in an undifferentiated state during the culture period. The transition of cells to differentiation can be evaluated by any method known to those skilled in the art. For example, in the case of skeletal myoblasts, MHC expression, creatine kinase (CK) activity, cell multinucleation, myotube formation, etc. can be used as indicators of differentiation. In a preferred embodiment of the present invention, the culture period is within 48 hours, more preferably within 40 hours, and even more preferably within 24 hours.
培養に用いる細胞培養液（単に「培養液」もしくは「培地」と呼ぶ場合もある）は、細胞の生存を維持できるものであれば特に限定されないが、典型的には、アミノ酸、ビタミン類、電解質を主成分としたものが利用できる。本発明の一態様において、培養液は、細胞培養用の基礎培地をベースにしたものである。かかる基礎培地には、限定されずに、例えば、ＤＭＥＭ、ＭＥＭ、Ｆ１２、ＤＭＥ、ＲＰＭＩ１６４０、ＭＣＤＢ（ＭＣＤＢ１０２、１０４、１０７、１３１、１５３、１９９など）、Ｌ１５、ＳｋＢＭ、ＲＩＴＣ８０－７などが含まれる。これらの基礎培地の多くは市販されており、その組成も公知となっている。一例として、下記表１にＭＣＤＢ１３１およびＤＭＥＭの組成を示す。 The cell culture medium used for culturing (sometimes simply called "culture medium" or "medium") is not particularly limited as long as it can maintain cell survival, but typically, a medium containing amino acids, vitamins, and electrolytes as its main components can be used. In one aspect of the present invention, the culture medium is based on a basal medium for cell culture. Such basal media include, but are not limited to, DMEM, MEM, F12, DME, RPMI1640, MCDB (MCDB102, 104, 107, 131, 153, 199, etc.), L15, SkBM, RITC80-7, etc. Many of these basal media are commercially available, and their compositions are also publicly known. As an example, the compositions of MCDB131 and DMEM are shown in Table 1 below.
基礎培地に含まれるアミノ酸としては、限定されずに、例えば、Ｌ－アルギニン、Ｌ－シスチン、Ｌ－グルタミン、グリシン、Ｌ－ヒスチジン、Ｌ－イソロイシン、Ｌ－ロイシン、Ｌ－リジン、Ｌ－メチオニン、Ｌ－フェニルアラニン、Ｌ－セリン、Ｌ－トレオニン、Ｌ－トリプトファン、Ｌ－チロシン、Ｌ－バリンなどが、ビタミン類としては、限定されずに、例えば、Ｄ－パントテン酸カルシウム、塩化コリン、葉酸、ｉ－イノシトール、ナイアシンアミド、リボフラビン、チアミン、ピリドキシン、ビオチン、リポ酸、ビタミンＢ１２、アデニン、チミジンなどが、そして、電解質としては、限定されずに、例えば、ＣａＣｌ２、ＫＣｌ、ＭｇＳＯ４、ＮａＣｌ、ＮａＨ２ＰＯ４、ＮａＨＣＯ３、Ｆｅ（ＮＯ３）３、ＦｅＳＯ４、ＣｕＳＯ４、ＭｎＳＯ４、Ｎａ２ＳｉＯ３、（ＮＨ４）６Ｍｏ７Ｏ２４、ＮａＶＯ３、ＮｉＣｌ２、ＺｎＳＯ４などがそれぞれ含まれる。基礎培地には、これらの成分のほか、Ｄ－グルコースなどの糖類、ピルビン酸ナトリウム、フェノールレッドなどのｐＨ指示薬、プトレシンなどを含んでもよい。 The amino acids contained in the basal medium are not limited to, for example, L-arginine, L-cystine, L-glutamine, glycine, L-histidine, L-isoleucine, L-leucine, L-lysine, L-methionine, L-phenylalanine, L-serine, L-threonine, L-tryptophan, L-tyrosine, and L-valine. The vitamins are not limited to, for example, D-calcium pantothenate, choline chloride, folic acid, i-inositol, niacinamide, riboflavin, thiamine, pyridoxine, biotin, lipoic acid, vitamin B 12 , adenine, and thymidine. The electrolytes are not limited to, for example, CaCl 2 , KCl, MgSO 4 , NaCl, NaH 2 PO 4 , NaHCO 3 , Fe(NO 3 ) 3 , FeSO 4 , CuSO 4 , MnSO 4 , Na 2SiO 3 , (NH 4 )6Mo 7 O 24 , NaVO 3 , NiCl 2 , ZnSO 4 , etc. In addition to these components, the basal medium may contain sugars such as D-glucose, sodium pyruvate, a pH indicator such as phenol red, putrescine, etc.
本発明の一態様において、基礎培地に含まれるアミノ酸の濃度は、Ｌ－アルギニン：６３．２～８４ｍｇ／Ｌ、Ｌ－シスチン：３５～６３ｍｇ／Ｌ、Ｌ－グルタミン：４．４～５８４ｍｇ／Ｌ、グリシン：２．３～３０ｍｇ／Ｌ、Ｌ－ヒスチジン：４２ｍｇ／Ｌ、Ｌ－イソロイシン：６６～１０５ｍｇ／Ｌ、Ｌ－ロイシン：１０５～１３１ｍｇ／Ｌ、Ｌ－リジン：１４６～１８２ｍｇ／Ｌ、Ｌ－メチオニン：１５～３０ｍｇ／Ｌ、Ｌ－フェニルアラニン：３３～６６ｍｇ／Ｌ、Ｌ－セリン：３２～４２ｍｇ／Ｌ、Ｌ－トレオニン：１２～９５ｍｇ／Ｌ、Ｌ－トリプトファン：４．１～１６ｍｇ／Ｌ、Ｌ－チロシン：１８．１～１０４ｍｇ／Ｌ、Ｌ－バリン：９４～１１７ｍｇ／Ｌである。
また、本発明の一態様において、基礎培地に含まれるビタミン剤の濃度は、Ｄ－パントテン酸カルシウム：４～１２ｍｇ／Ｌ、塩化コリン：４～１４ｍｇ／Ｌ、葉酸：０．６～４ｍｇ／Ｌ、ｉ－イノシトール：７．２ｍｇ／Ｌ、ナイアシンアミド：４～６．１ｍｇ／Ｌ、リボフラビン：０．００３８～０．４ｍｇ／Ｌ、チアミン：３．４～４ｍｇ／Ｌ、ピリドキシン：２．１～４ｍｇ／Ｌである。
In one embodiment of the present invention, the concentrations of amino acids contained in the basal medium are as follows: L-arginine: 63.2 to 84 mg/L, L-cystine: 35 to 63 mg/L, L-glutamine: 4.4 to 584 mg/L, glycine: 2.3 to 30 mg/L, L-histidine: 42 mg/L, L-isoleucine: 66 to 105 mg/L, L-leucine: 105 to 131 mg/L, L-lysine: 146 to 182 mg/L, L-methionine: 15 to 30 mg/L, L-phenylalanine: 33 to 66 mg/L, L-serine: 32 to 42 mg/L, L-threonine: 12 to 95 mg/L, L-tryptophan: 4.1 to 16 mg/L, L-tyrosine: 18.1 to 104 mg/L, and L-valine: 94 to 117 mg/L.
In one embodiment of the present invention, the concentrations of vitamin supplements contained in the basal medium are as follows: D-calcium pantothenate: 4 to 12 mg/L, choline chloride: 4 to 14 mg/L, folic acid: 0.6 to 4 mg/L, i-inositol: 7.2 mg/L, niacinamide: 4 to 6.1 mg/L, riboflavin: 0.0038 to 0.4 mg/L, thiamine: 3.4 to 4 mg/L, and pyridoxine: 2.1 to 4 mg/L.
細胞培養液は、上記のほか、血清、成長因子、ステロイド剤成分、セレン成分などの１種または２種以上の添加物を含んでもよい。しかし、これらの成分は臨床においてはレシピエントに対するアナフィラキシーショック等の副作用要因となり得ることが否定できない製造工程由来不純物であり、臨床への適用にあたっては排除すべき成分である。したがって、本発明の好ましい態様において、細胞培養液は、これらの添加物の少なくとも１種の有効量を含まない。また、本発明のより好ましい態様において、細胞培養液は、これらの添加物の少なくとも１種を実質的に含まない。さらに、本発明の特に好ましい態様において、細胞培養液は、添加物を実質的に含まない。したがって、細胞培養液は、基礎培地のみを含んでもよい。 In addition to the above, the cell culture medium may contain one or more additives such as serum, growth factors, steroid components, and selenium components. However, these components are impurities derived from the manufacturing process that may cause side effects such as anaphylactic shock in recipients in clinical settings, and are components that should be excluded when applied to clinical settings. Therefore, in a preferred embodiment of the present invention, the cell culture medium does not contain an effective amount of at least one of these additives. Also, in a more preferred embodiment of the present invention, the cell culture medium is substantially free of at least one of these additives. Furthermore, in a particularly preferred embodiment of the present invention, the cell culture medium is substantially free of additives. Therefore, the cell culture medium may contain only a basal medium.
細胞培養液に含まれる血清としては、異種血清および同種血清が挙げられる、ここで「異種血清」は、細胞培養物を移植に用いる場合、そのレシピエントとは異なる種の生物に由来する血清を意味する。例えば、レシピエントがヒトである場合、ウシやウマに由来する血清、例えば、ウシ胎仔血清（ＦＢＳ、ＦＣＳ）、仔ウシ血清（ＣＳ）、ウマ血清（ＨＳ）などが異種血清に該当する。また、「同種血清」は、レシピエントと同一の種の生物に由来する血清を意味する。例えば、レシピエントがヒトである場合、ヒト血清が同種血清に該当する。同種血清は、自己血清、すなわち、レシピエントに由来する血清、およびレシピエント以外の同種個体に由来する同種他家血清を含む。なお、本明細書中で、自己血清以外の血清、すなわち、異種血清と同種他家血清を非自己血清と総称することもある。本発明においては、移植時の副作用を回避するために、同種血清が好ましく、自己血清がさらに好ましい。 Examples of serum contained in the cell culture medium include xenogeneic serum and allogeneic serum. Here, "xenogeneic serum" refers to serum derived from an organism of a different species from the recipient when the cell culture is used for transplantation. For example, when the recipient is a human, serum derived from a cow or horse, such as fetal bovine serum (FBS, FCS), calf serum (CS), and horse serum (HS), corresponds to xenogeneic serum. "Allogeneic serum" refers to serum derived from an organism of the same species as the recipient. For example, when the recipient is a human, human serum corresponds to allogeneic serum. Allogeneic serum includes autologous serum, i.e., serum derived from the recipient, and allogeneic serum derived from an individual of the same species other than the recipient. In this specification, serum other than autologous serum, i.e., xenogeneic serum and allogeneic serum, may be collectively referred to as non-autologous serum. In the present invention, allogeneic serum is preferred, and autogeneic serum is more preferred, in order to avoid side effects during transplantation.
本発明の一態様において、細胞培養液は血清を実質的に含まない。血清を実質的に含まない細胞培養液のことを、本明細書中で「無血清培地」と呼ぶこともある。ここで、「血清を実質的に含まない」とは、培養液における血清の含量が、細胞培養物を生体に適用した場合に悪影響を及ぼさない程度（例えば、細胞培養物中の血清アルブミン含量が５０ｎｇ未満となる量）であること、好ましくは、培養液にこれらの物質を積極的に添加しないことを意味する。本発明においては、移植時の副作用を回避するために、細胞培養液は異種血清を実質的に含まないことが好ましく、非自己血清を実質的に含まないことがさらに好ましい。 In one embodiment of the present invention, the cell culture medium is substantially free of serum. A cell culture medium that is substantially free of serum is sometimes referred to herein as a "serum-free medium." Here, "substantially free of serum" means that the content of serum in the culture medium is at a level that does not adversely affect the application of the cell culture to a living body (e.g., an amount that results in a serum albumin content of less than 50 ng in the cell culture), and preferably, these substances are not actively added to the culture medium. In the present invention, in order to avoid side effects during transplantation, it is preferable that the cell culture medium is substantially free of xenogeneic serum, and more preferably, is substantially free of non-autologous serum.
本発明の一態様において、細胞培養液は有効量の成長因子を含まない。ここで、「成長因子」は、細胞の増殖を、それがない場合に比べて促進する任意の物質を意味し、例えば、上皮細胞成長因子（ＥＧＦ）、血管内皮成長因子（ＶＥＧＦ）、線維芽細胞成長因子（ＦＧＦ）などを含む。また、「有効量の成長因子」とは、細胞の増殖を、成長因子がない場合に比べて、有意に促進する成長因子の量、または、便宜的に、当該技術分野において細胞の増殖を目的として通常添加する量を意味する。細胞増殖促進の有意性は、例えば、当該技術分野で知られた任意の統計学的手法、例えば、ｔ検定などにより適宜評価することができ、また、通常の添加量は当該技術分野の種々の公知文献から知ることができる。具体的には、骨格筋芽細胞の培養におけるＥＧＦの有効量は、例えば０．００５μｇ／ｍＬ以上である。 In one embodiment of the present invention, the cell culture medium does not contain an effective amount of growth factor. Here, "growth factor" means any substance that promotes cell proliferation compared to the absence of the growth factor, and includes, for example, epidermal growth factor (EGF), vascular endothelial growth factor (VEGF), fibroblast growth factor (FGF), etc. Also, "effective amount of growth factor" means an amount of growth factor that significantly promotes cell proliferation compared to the absence of the growth factor, or, for convenience, an amount that is usually added for the purpose of cell proliferation in the relevant technical field. The significance of the promotion of cell proliferation can be appropriately evaluated, for example, by any statistical method known in the relevant technical field, such as a t-test, and the usual amount to be added can be known from various publicly known documents in the relevant technical field. Specifically, the effective amount of EGF in the culture of skeletal myoblasts is, for example, 0.005 μg/mL or more.
したがって、「有効量の成長因子を含まない」とは、本発明における培養液における成長因子の濃度がかかる有効量未満であることを意味する。例えば、骨格筋芽細胞の培養におけるＥＧＦの培養液中の濃度は、好ましくは０．００５μｇ／ｍＬ未満、より好ましくは０．００１μｇ／ｍＬ未満である。本発明の好ましい態様においては、培養液における成長因子の濃度は、生体における通常の濃度未満である。かかる態様においては、例えば、骨格筋芽細胞の培養におけるＥＧＦの培養液中の濃度は、好ましくは５．５ｎｇ／ｍＬ未満、より好ましくは１．３ｎｇ／ｍＬ未満、さらに好ましくは、０．５ｎｇ／ｍＬ未満である。さらに好ましい態様において、本発明における培養液は、成長因子を実質的に含まない。ここで、実質的に含まないとは、培養液中の成長因子の含量が、細胞培養物を生体に適用した場合に悪影響を及ぼさない程度であること、好ましくは、培養液に成長因子を積極的に添加しないことを意味する。したがって、この態様においては、培養液は、その中の他の成分、例えば血清などに含まれる以上の濃度の成長因子を含まない。 Therefore, "not containing an effective amount of growth factor" means that the concentration of growth factor in the culture medium in the present invention is less than the effective amount. For example, the concentration of EGF in the culture medium in the culture of skeletal myoblasts is preferably less than 0.005 μg/mL, more preferably less than 0.001 μg/mL. In a preferred embodiment of the present invention, the concentration of growth factor in the culture medium is less than the normal concentration in a living body. In such an embodiment, for example, the concentration of EGF in the culture medium in the culture of skeletal myoblasts is preferably less than 5.5 ng/mL, more preferably less than 1.3 ng/mL, and even more preferably less than 0.5 ng/mL. In a more preferred embodiment, the culture medium in the present invention is substantially free of growth factors. Here, "substantially free" means that the content of growth factors in the culture medium is at a level that does not have a negative effect when the cell culture is applied to a living body, and preferably, growth factors are not actively added to the culture medium. Therefore, in this embodiment, the culture medium does not contain growth factors at a concentration greater than that contained in other components therein, such as serum.
本発明の一態様において、細胞培養液は、ステロイド剤成分を実質的に含まない。ここで「ステロイド剤成分」は、ステロイド核を有する化合物のうち、生体に、副腎皮質機能不全、クッシング症候群などの悪影響を及ぼし得るものをいう。かかる化合物としては、限定されずに、例えば、コルチゾール、プレドニゾロン、トリアムシノロン、デキサメタゾン、ベタメタゾン等が含まれる。したがって、「ステロイド剤成分を実質的に含まない」とは、培養液におけるこれらの化合物の含量が、細胞培養物を生体に適用した場合に悪影響を及ぼさない程度であること、好ましくは、培養液にこれらの化合物を積極的に添加しないこと、すなわち、培養液が、その中の他の成分、例えば血清などに含まれる以上の濃度のステロイド剤成分を含まないことを意味する。 In one embodiment of the present invention, the cell culture medium is substantially free of steroid components. Here, "steroid components" refers to compounds having a steroid nucleus that may have adverse effects on the living body, such as adrenal insufficiency and Cushing's syndrome. Such compounds include, but are not limited to, cortisol, prednisolone, triamcinolone, dexamethasone, betamethasone, and the like. Therefore, "substantially free of steroid components" means that the content of these compounds in the culture medium is at a level that does not have adverse effects when the cell culture is applied to a living body, and preferably that these compounds are not actively added to the culture medium, that is, the culture medium does not contain steroid components at a concentration higher than that contained in other components therein, such as serum.
本発明の一態様において、細胞培養液は、セレン成分を実質的に含まない。ここで「セレン成分」は、セレン分子、およびセレン含有化合物、特に、生体内でセレン分子を遊離し得るセレン含有化合物、例えば、亜セレン酸などを含む。したがって、「セレン成分を実質的に含まない」とは、培養液におけるこれらの物質の含量が、細胞培養物を生体に適用した場合に悪影響を及ぼさない程度であること、好ましくは、培養液にこれらの物質を積極的に添加しないこと、すなわち、培養液が、その中の他の成分、例えば血清などに含まれる以上の濃度のセレン成分を含まないことを意味する。具体的には、例えば、ヒトの場合、培養液中のセレン濃度は、ヒト血清中の正常値（例えば、１０．６～１７．４μｇ／ｄＬ）に、培地中に含まれるヒト血清の割合を乗じた値よりも低い（すなわち、ヒト血清の含量が１０％であれば、セレン濃度は、例えば、１．０～１．７μｇ／ｄＬ未満である）。 In one aspect of the present invention, the cell culture medium is substantially free of selenium components. Here, "selenium components" includes selenium molecules and selenium-containing compounds, particularly selenium-containing compounds that can release selenium molecules in vivo, such as selenite. Therefore, "substantially free of selenium components" means that the content of these substances in the culture medium is at a level that does not adversely affect the application of the cell culture to a living body, and preferably that these substances are not actively added to the culture medium, that is, the culture medium does not contain selenium components at a concentration higher than that contained in other components therein, such as serum. Specifically, for example, in the case of humans, the selenium concentration in the culture medium is lower than the normal value in human serum (e.g., 10.6 to 17.4 μg/dL) multiplied by the proportion of human serum contained in the medium (i.e., if the content of human serum is 10%, the selenium concentration is, for example, less than 1.0 to 1.7 μg/dL).
本発明の上記好ましい態様においては、生体に適用する細胞培養物を作製する場合に従来必要であった、成長因子、ステロイド剤成分、異種血清成分などの製造工程由来不純物を、洗浄などにより除去する工程が不要となる。したがって、本発明の方法の一態様は、この製造工程由来不純物を除去する工程を含まない。
ここで、「製造工程由来不純物」とは、典型的には、製造各工程に由来する以下に列挙するものが含まれる。すなわち、細胞基材に由来するもの（例えば、宿主細胞由来タンパク質、宿主細胞由来ＤＮＡ）、細胞培養液に由来するもの（例えば、インデューサー、抗生物質、培地成分）、あるいは細胞培養以降の工程である目的物質の抽出、分離、加工、精製工程に由来するものなどである（例えば、医薬審発第５７１号参照）。
In the above-mentioned preferred embodiment of the present invention, the step of removing impurities derived from the manufacturing process, such as growth factors, steroid components, xenogenic serum components, etc., by washing or the like, which has been conventionally required when preparing a cell culture for application to a living body, is not required. Thus, one embodiment of the method of the present invention does not include the step of removing the impurities derived from the manufacturing process.
Here, "impurities derived from the manufacturing process" typically include the following impurities derived from each manufacturing process: those derived from the cell substrate (e.g., host cell-derived proteins, host cell-derived DNA), those derived from the cell culture medium (e.g., inducers, antibiotics, medium components), and those derived from the extraction, separation, processing, and purification processes of the target substance that are steps subsequent to cell culture (see, for example, Notification No. 571 of the Pharmaceutical and Medical Devices Agency).
また、本発明の方法により製造されたシート状細胞培養物は、洗浄操作に耐え得る物理的強度を有しているため、本発明の方法は、上記製造工程由来不純物等を洗浄などにより除去する工程を含んでもよい。したがって、本発明の一態様は、単離したシート状細胞培養物を洗浄する工程をさらに含む。かかる工程を加えることにより、上記製造工程由来不純物を実質的に含む細胞培養液を用いても、かかる不純物を実質的に含まないシート状細胞培養物を得ることが可能となる。 In addition, since the sheet-shaped cell culture produced by the method of the present invention has a physical strength that can withstand washing operations, the method of the present invention may include a step of removing impurities derived from the above-mentioned manufacturing process by washing or the like. Therefore, one aspect of the present invention further includes a step of washing the isolated sheet-shaped cell culture. By adding such a step, it is possible to obtain a sheet-shaped cell culture that is substantially free of impurities derived from the above-mentioned manufacturing process, even when a cell culture solution that substantially contains such impurities is used.
細胞の培養は、当該技術分野で通常なされている条件で行うことができる。例えば、典型的な培養条件としては、３７℃、５％ＣＯ２での培養が挙げられる。培養期間は、細胞培養物の十分な形成、および、細胞分化防止の観点から、好ましくは４８時間以内、より好ましくは４０時間以内、さらに好ましくは２４時間以内である。培養は任意の大きさおよび形状の容器で行うことができる。本発明の方法において、細胞は実質的に増殖しないため、従来の方法のように細胞培養物が所望の大きさに成長するのを待つことなく、所望の大きさおよび形状の細胞培養物を短期間で得ることが可能となる。細胞培養物の大きさや形状は、培養容器の細胞付着面の大きさ・形状を調整すること、または、培養容器の細胞付着面に、所望の大きさ・形状の型枠を設置し、その内部で細胞を培養することなどにより任意に調節することができる。 The cell culture can be carried out under conditions that are generally used in the art. For example, typical culture conditions include culture at 37°C and 5% CO2 . The culture period is preferably within 48 hours, more preferably within 40 hours, and even more preferably within 24 hours, from the viewpoint of sufficient formation of the cell culture and prevention of cell differentiation. The culture can be carried out in a vessel of any size and shape. In the method of the present invention, the cells do not substantially grow, so that it is possible to obtain a cell culture of a desired size and shape in a short period of time without waiting for the cell culture to grow to a desired size as in the conventional method. The size and shape of the cell culture can be arbitrarily adjusted by adjusting the size and shape of the cell attachment surface of the culture vessel, or by placing a mold of a desired size and shape on the cell attachment surface of the culture vessel and culturing the cells inside it.
本方法は、細胞培養物を培養基材から単離する工程をさらに含んでもよい。細胞培養物の基材からの単離は、細胞培養物が少なくとも部分的に、シート構造を保ったまま、足場となっている基材から遊離（剥離）できれば特に限定されず、例えば、タンパク分解酵素、例えばトリプシンによる酵素処理および／または浸漬撹拌、ピペッティングなどの機械的処理によって行うことができる。また、細胞を、刺激、例えば、温度や光に応答して物性が変化する材料で表面を被覆した培養基材上で培養して細胞培養物を形成させることにより、所定の刺激を加えることで、非酵素的に遊離することもできる。 The method may further include a step of isolating the cell culture from the culture substrate. Isolation of the cell culture from the substrate is not particularly limited as long as the cell culture can be at least partially released (detached) from the substrate that serves as a scaffold while maintaining the sheet structure, and can be performed, for example, by enzymatic treatment with a proteolytic enzyme, such as trypsin, and/or mechanical treatment such as immersion stirring or pipetting. In addition, cells can be non-enzymatically released by applying a predetermined stimulus, for example, by culturing the cells on a culture substrate whose surface is coated with a material whose physical properties change in response to a stimulus, such as temperature or light, to form a cell culture.
本発明の方法は、細胞の採取から、細胞の増殖および細胞培養物の作製を経て、細胞培養物の適用に至る、再生治療の一工程として位置づけることもできる。したがって、本発明は、
（ｉ）対象から採取した組織または生体液から所望の細胞を単離する工程、
（ｉｉ）単離した細胞を増殖させる工程、
（ｉｉｉ）血清で被覆された培養基材上に、実質的に増殖することなくシート状細胞培養物を形成し得る密度の細胞を播種する工程、
（ｉｖ）細胞を培養してシート状の細胞培養物を形成する工程、および
（ｖ）形成された培養物を基材から単離する工程、および任意に
（ｖｉ）単離したシート状細胞培養物を洗浄する工程
を含む、再生治療用シート状細胞培養物の製造方法にも関する。
The method of the present invention can be considered as one step in regenerative therapy, from cell collection, through cell proliferation and preparation of a cell culture, to application of the cell culture.
(i) isolating desired cells from a tissue or biological fluid obtained from a subject;
(ii) expanding the isolated cells;
(iii) seeding cells on a serum-coated culture substrate at a density sufficient to form a sheet-shaped cell culture without substantial proliferation;
The present invention also relates to a method for producing a sheet-shaped cell culture for regenerative therapy, comprising the steps of (iv) culturing cells to form a sheet-shaped cell culture, (v) isolating the formed culture from the substrate, and, optionally, (vi) washing the isolated sheet-shaped cell culture.
本発明はまた、上記製造方法によって作製されたシート状細胞培養物に関する。
好ましい態様において、本発明のシート状細胞培養物は、浸漬撹拌などの洗浄操作や、取出し、保持、移送などの移植操作に対して十分な物理的強度を有する。十分な物理的強度を有するとは、上記操作を施しても細胞培養物のシート状構造が損なわれないことを意味し、これは、例えば、得られたシート状細胞培養物に実際に上記操作を施し、シート状構造が保たれていることを肉眼的または顕微鏡的に調査することにより確認することができる。ここで、浸漬撹拌による洗浄操作とは、典型的には、シート状細胞培養物の入った培養容器に同培養物が十分浸漬する量の緩衝液を加え、培養容器ごと振とう撹拌することをいう。したがって、十分な物理的強度を有することは、かかる浸漬撹拌による洗浄操作と同様の物理的ストレスをシート状細胞培養物に加えることによっても確認することができる。また、上記製造方法によって作製されたシート状細胞培養物であれば、通常かかる十分な物理的強度を有する。
The present invention also relates to a sheet-shaped cell culture produced by the above-mentioned production method.
In a preferred embodiment, the sheet-shaped cell culture of the present invention has sufficient physical strength against washing operations such as immersion and agitation, and transplantation operations such as removal, holding, and transfer. Having sufficient physical strength means that the sheet-shaped structure of the cell culture is not damaged even when the above operations are performed, and this can be confirmed, for example, by actually performing the above operations on the obtained sheet-shaped cell culture and examining with the naked eye or a microscope that the sheet-shaped structure is maintained. Here, the washing operation by immersion and agitation typically refers to adding a buffer solution to a culture vessel containing a sheet-shaped cell culture in an amount that allows the culture to be fully immersed, and shaking and agitating the culture vessel together. Therefore, having sufficient physical strength can also be confirmed by applying the same physical stress as the washing operation by immersion and agitation to the sheet-shaped cell culture. In addition, a sheet-shaped cell culture produced by the above production method usually has such sufficient physical strength.
本発明の細胞培養物の好ましい態様において、細胞培養物は非自己血清、成長因子、ステロイド剤および／またはセレン成分を実質的に含まない。より好ましい態様において、本発明の細胞培養物は、上記成分を含む製造工程由来不純物を実質的に含まない。この細胞培養物は、細胞を、非自己血清、成長因子、ステロイド剤および／またはセレン成分を実質的に含まない培養液で培養して、細胞培養物を形成させることにより作製することができる。ここで、細胞培養物が非自己血清、成長因子、ステロイド剤および／またはセレン成分を実質的に含まないとは、細胞培養物が、これらの成分を、レシピエントに悪影響を与える濃度で含まないことを少なくとも意味するが、細胞培養物の形成を、非自己血清、成長因子、ステロイド剤および／またはセレン成分を実質的に含まない培養液で行うことにより、かかる条件を充足することができる。さらに好ましい態様において、本発明の細胞培養物は、製造工程由来不純物のほか、自己血清も実質的に含まない。ここで、「実質的に含まない」の意味は、上記と同様である。 In a preferred embodiment of the cell culture of the present invention, the cell culture is substantially free of non-autologous serum, growth factors, steroids, and/or selenium components. In a more preferred embodiment, the cell culture of the present invention is substantially free of impurities derived from the manufacturing process, including the above-mentioned components. This cell culture can be produced by culturing cells in a culture medium that is substantially free of non-autologous serum, growth factors, steroids, and/or selenium components to form a cell culture. Here, the cell culture being substantially free of non-autologous serum, growth factors, steroids, and/or selenium components at least means that the cell culture does not contain these components at concentrations that adversely affect the recipient, but such a condition can be met by forming the cell culture in a culture medium that is substantially free of non-autologous serum, growth factors, steroids, and/or selenium components. In a further preferred embodiment, the cell culture of the present invention is substantially free of autologous serum as well as impurities derived from the manufacturing process. Here, the meaning of "substantially free" is the same as above.
本発明の細胞培養物の好ましい態様において、細胞培養物は炎症性サイトカインが低減されている。炎症性サイトカインとは、炎症に伴い産生されるサイトカインの総称であり、例えば、限定することなく、ＴＮＦ－α、ＩＬ－１（ＩＬ－１α、ＩＬ－１βなど）、ＩＬ－４、ＩＬ－５、ＩＬ－６、ＩＬ－１３などが挙げられる。したがって、「炎症性サイトカインが低減されている」とは、これらのサイトカインの存在量または産生量（分泌量）が、分化した細胞培養物に比べて低減していることを意味する。したがって、サイトカインは、遺伝子の転写からタンパク質の分泌に至る過程のいずれにおける形態で存在してもよく、例えば、ｍＲＮＡなどの転写物の形態や、タンパク質の形態で存在していてもよい。低減の程度は、誤差の範囲を超えるものであれば特に限定されないが、例えば、分化した細胞培養物に比べて１５％以上、好ましくは２５％以上、より好ましくは５０％以上、さらに好ましくは６０％以上、特に好ましくは７０％以上の低減である。 In a preferred embodiment of the cell culture of the present invention, the cell culture has reduced levels of inflammatory cytokines. Inflammatory cytokines are a general term for cytokines produced in association with inflammation, and include, but are not limited to, TNF-α, IL-1 (IL-1α, IL-1β, etc.), IL-4, IL-5, IL-6, IL-13, etc. Thus, "reduced levels of inflammatory cytokines" means that the amount of these cytokines present or produced (secreted) is reduced compared to differentiated cell cultures. Thus, cytokines may be present in any form during the process from gene transcription to protein secretion, and may be present in the form of a transcript such as mRNA or in the form of a protein. The degree of reduction is not particularly limited as long as it exceeds the margin of error, but is, for example, a reduction of 15% or more, preferably 25% or more, more preferably 50% or more, even more preferably 60% or more, and particularly preferably 70% or more compared to differentiated cell cultures.
サイトカインの量は、遺伝子レベルでは、例えば、ノーザンブロッティング法、サザンブロッティング法、ＲＮａｓｅプロテクションアッセイ、ＲＴ－ＰＣＲ、リアルタイムＰＣＲ等のＰＣＲ法、in situハイブリダイゼーション法、in vitro転写法等の任意の公知の遺伝子発現解析法により、また、タンパク質レベルでは、免疫沈降法、ウェスタンブロッティング法、ＥＩＡ、ＥＬＩＳＡ、ＲＩＡ、免役組織化学法、免疫細胞化学法等の任意の公知のタンパク質検出法により検出することができる。検体としては、細胞培養物が含浸された培地や、細胞培養物の一部などを用いることができる。 The amount of cytokines can be detected at the gene level by any known gene expression analysis method, such as Northern blotting, Southern blotting, RNase protection assay, PCR such as RT-PCR and real-time PCR, in situ hybridization, in vitro transcription, etc., and at the protein level by any known protein detection method, such as immunoprecipitation, Western blotting, EIA, ELISA, RIA, immunohistochemistry, immunocytochemistry, etc. Samples that can be used include culture media impregnated with cell cultures and parts of cell cultures.
本発明の好ましい態様において、細胞培養物は治療上有用な生理活性物質を含む。かかる物質は、治療上何らかの有用性を有するものであれば特に限定されないが、例えば、血管新生、細胞死の抑制、組織リモデリング、心臓発生、幹細胞の誘導等に関与する物質を含み、より具体的には、限定されずに、例えば、ＶＥＧＦ、ＰＩＧＦ、アンギオゲニン、アンギオポエチン、ＨＧＦ、ＰＤＧＦ（ＰＤＧＦ－ＡＢ、ＰＤＧＦ－ＢＢなど）、ＢＡＧ－１、ＢＣＬ－２、ＭＭＰ（ＭＭＰ－２、ＭＭＰ－３、ＭＭＰ－９、ＭＭＰ－１０など）、ＴＩＭＰ、ＴＮＮＴ２、ＴＮＮＣ１、ＩＧＦ－１などが挙げられる。 In a preferred embodiment of the present invention, the cell culture contains a therapeutically useful physiologically active substance. Such substances are not particularly limited as long as they have some therapeutic utility, and include, for example, substances involved in angiogenesis, inhibition of cell death, tissue remodeling, cardiogenesis, stem cell induction, etc., and more specifically, examples of such substances include, but are not limited to, VEGF, PIGF, angiogenin, angiopoietin, HGF, PDGF (PDGF-AB, PDGF-BB, etc.), BAG-1, BCL-2, MMP (MMP-2, MMP-3, MMP-9, MMP-10, etc.), TIMP, TNNT2, TNNC1, IGF-1, etc.
これらの物質を「含む」とは、これらの存在量または産生量（分泌量）が細胞培養物において検出できることを意味する。本発明の好ましい態様において、細胞培養物は、これらの物質を分化した細胞培養物よりも多く含む。増大の程度は、誤差の範囲を超えるものであれば特に限定されないが、例えば、分化した細胞培養物に比べて１．２倍以上、好ましくは１．５倍以上、より好ましくは２倍以上、さらに好ましくは３倍以上である。これらの物質は、遺伝子の転写からタンパク質の分泌に至る過程のいずれにおける形態で存在してもよく、例えば、ｍＲＮＡなどの転写物の形態や、タンパク質の形態で存在していてもよい。これらの物質の存在は、上記のサイトカインと同様に検出および／または定量できる。 "Containing" these substances means that the amount of these substances present or produced (secreted) can be detected in the cell culture. In a preferred embodiment of the present invention, the cell culture contains more of these substances than the differentiated cell culture. The degree of increase is not particularly limited as long as it exceeds the margin of error, but for example, it is 1.2 times or more, preferably 1.5 times or more, more preferably 2 times or more, and even more preferably 3 times or more compared to the differentiated cell culture. These substances may exist in any form during the process from gene transcription to protein secretion, for example, in the form of a transcript such as mRNA or in the form of a protein. The presence of these substances can be detected and/or quantified in the same manner as the above-mentioned cytokines.
本発明の好ましい態様において、細胞培養物は未分化の状態である。細胞の分化への移行は、当業者に知られた任意の方法で評価することができる。例えば、骨格筋芽細胞の場合は、ＭＨＣの発現、クレアチンキナーゼ（ＣＫ）活性、細胞の多核化などを分化の指標とすることができる。また、未分化細胞では、分化細胞に比べて炎症性サイトカインが少なく、治療上有用な生理活性物質が多いことから、これを指標に分化の有無を判断することもできる。未分化の状態の細胞培養物を得る手法としては、例えば、細胞を本発明の方法に従って、４８時間以内、より好ましくは４０時間以内、さらに好ましくは２４時間以内の期間培養することが挙げられる。 In a preferred embodiment of the present invention, the cell culture is in an undifferentiated state. The transition to cell differentiation can be evaluated by any method known to those skilled in the art. For example, in the case of skeletal myoblasts, MHC expression, creatine kinase (CK) activity, cell multinucleation, etc. can be used as indicators of differentiation. In addition, since undifferentiated cells have fewer inflammatory cytokines and more therapeutically useful physiologically active substances than differentiated cells, the presence or absence of differentiation can be determined using these indicators. A method for obtaining a cell culture in an undifferentiated state can be, for example, culturing cells according to the method of the present invention for a period of 48 hours or less, more preferably 40 hours or less, and even more preferably 24 hours or less.
本発明の細胞培養物は、対象の疾病、傷病の治療に用いることができる。例えば、骨格筋芽細胞による細胞培養物は、心疾患、例えば、心筋梗塞、拡張型心筋症などに、移植片などの形態で用いることができる。したがって、本発明の別の態様は、上記細胞培養物を含む移植片に関する。 The cell culture of the present invention can be used to treat a disease or injury of a subject. For example, a cell culture of skeletal myoblasts can be used in the form of a graft or the like for cardiac diseases such as myocardial infarction and dilated cardiomyopathy. Therefore, another aspect of the present invention relates to a graft containing the above-mentioned cell culture.
本発明はまた、血清および／または成長因子および／またはステロイド剤がコートされた培養基材に関する。本発明の培養基材は、このましくは、上記の本発明によるシート状細胞培養物の製造に用いられる。コートの手法などは、本発明のシート状細胞培養物の製造方法に関して上記したとおりである。
本発明はさらに、（ｉ）培養基材を血清と共にインキュベートする工程、および（ｉｉ）血清を廃棄する工程を含む、上記培養基材の製造方法に関する。具体的な製造手法は、本発明のシート状細胞培養物の製造方法に関して上記したとおりである。本発明の一態様において、工程（ｉｉ）の後に、（ｉｉｉ）培養基材を無血清洗浄液で洗浄する工程が追加されてもよい。
The present invention also relates to a culture substrate coated with serum and/or growth factors and/or steroids. The culture substrate of the present invention is preferably used for producing the sheet-shaped cell culture according to the present invention. The coating method and the like are as described above for the method for producing the sheet-shaped cell culture of the present invention.
The present invention further relates to a method for producing the above culture substrate, comprising the steps of (i) incubating the culture substrate with serum, and (ii) discarding the serum. The specific production method is as described above for the method for producing the sheet-shaped cell culture of the present invention. In one embodiment of the present invention, after the step (ii), a step (iii) of washing the culture substrate with a serum-free washing solution may be added.
本発明はさらにまた、培養基材と、血清、成長因子、ステロイド剤からなる群から選択されるコーティング剤とを含む、上記培養基材の製造キットに関する。同キットにおいて、コーティング剤は、種々の保存可能な形態、例えば、冷蔵、冷凍または凍結乾燥された状態で、適切な容器、例えば、種々の材質（ガラス、プラスチックなど）のバイアル、アンプル、ボトル、チューブ等に収納されていてもよい。本発明のキットは、上記のほか、コーティング剤を希釈および／または再構成するための媒体、例えば、水、生理食塩水、種々の緩衝液（例えば、ＰＢＳ、ＨＢＳなど）、種々の液体培地（例えば、ＤＭＥＭ、ＭＥＭ、Ｆ１２、ＤＭＥ、ＲＰＭＩ１６４０、ＭＣＤＢ（ＭＣＤＢ１０２、１０４、１０７、１３１、１５３、１９９など）、Ｌ１５、ＳｋＢＭ、ＲＩＴＣ８０－７、ＤＭＥＭ／Ｆ１２など）、ならびに、培養基材のコーティング手法に関する情報を含む説明書や、ＣＤ、ＤＶＤ等の電子記録媒体などを含んでいてもよい。本キットに含まれる培養基材やコーティング剤等は、好ましくは滅菌された状態で提供することができる。滅菌手法としては、限定することなく、エチレンオキサイドガスなどによるガス滅菌、紫外線や放射線（例えばγ線）による滅菌などが挙げられる。 The present invention further relates to a kit for producing the above-mentioned culture substrate, comprising a culture substrate and a coating agent selected from the group consisting of serum, growth factors, and steroids. In the kit, the coating agent may be stored in various storage forms, for example, in a refrigerated, frozen, or lyophilized state, in an appropriate container, for example, a vial, an ampoule, a bottle, a tube, etc. made of various materials (glass, plastic, etc.). In addition to the above, the kit of the present invention may also include a medium for diluting and/or reconstituting the coating agent, for example, water, physiological saline, various buffer solutions (for example, PBS, HBS, etc.), various liquid media (for example, DMEM, MEM, F12, DME, RPMI1640, MCDB (MCDB102, 104, 107, 131, 153, 199, etc.), L15, SkBM, RITC80-7, DMEM/F12, etc.), as well as instructions containing information on the coating method of the culture substrate, electronic recording media such as CDs and DVDs, etc. The culture substrate, coating agent, etc. contained in the kit can be provided preferably in a sterilized state. Sterilization techniques include, but are not limited to, gas sterilization using ethylene oxide gas, ultraviolet light, or radiation (e.g., gamma rays).
本発明はまた、細胞培養物を未分化状態に維持することによる、細胞培養物における炎症性サイトカインを低減する方法に関する。本発明はさらに、細胞培養物を未分化状態に維持することによる、細胞培養物に含まれる治療上有用な生理活性物質の低減を抑制する方法に関する。これらの方法において、細胞培養物を未分化状態に維持する手法としては、例えば、細胞の培養を、所定の期間内、好ましくは、細胞が分化に移行しない期間内に行うことが挙げられる。これらの方法の好ましい態様において、培養期間は４８時間以内、より好ましくは４０時間以内、さらに好ましくは２４時間以内である。これらの方法における各工程、炎症性サイトカインおよび治療上有用な生理活性物質は、基本的に、本発明のシート状細胞培養物の製造方法およびシート状細胞培養物に関して上記したとおりである。これらの方法において、「炎症性サイトカインを低減する」とは、これらのサイトカインの存在量または産生量（分泌量）を、分化した細胞培養物に比べて低減させることを意味する。低減の程度は、誤差の範囲を超えるものであれば特に限定されないが、例えば、分化した細胞培養物に比べて１５％以上、好ましくは２５％以上、より好ましくは５０％以上、さらに好ましくは６０％以上、特に好ましくは７０％以上の低減である。また、「治療上有用な生理活性物質の低減を抑制する」とは、これらの物質の存在量または産生量（分泌量）を、分化した細胞培養物に比べて増大した状態に維持することを意味する。増大の程度は、誤差の範囲を超えるものであれば特に限定されないが、例えば、分化した細胞培養物に比べて１．２倍以上、好ましくは１．５倍以上、より好ましくは２倍以上、さらに好ましくは３倍以上である。 The present invention also relates to a method for reducing inflammatory cytokines in a cell culture by maintaining the cell culture in an undifferentiated state. The present invention further relates to a method for suppressing a reduction in a therapeutically useful physiologically active substance contained in a cell culture by maintaining the cell culture in an undifferentiated state. In these methods, a method for maintaining a cell culture in an undifferentiated state includes, for example, culturing the cells within a predetermined period, preferably within a period during which the cells do not differentiate. In a preferred embodiment of these methods, the culture period is 48 hours or less, more preferably 40 hours or less, and even more preferably 24 hours or less. The steps, inflammatory cytokines, and therapeutically useful physiologically active substances in these methods are basically as described above for the method for producing a sheet-shaped cell culture and the sheet-shaped cell culture of the present invention. In these methods, "reducing inflammatory cytokines" means reducing the amount of these cytokines present or the amount produced (secreted) compared to a differentiated cell culture. The degree of reduction is not particularly limited as long as it exceeds the range of error, but is, for example, a reduction of 15% or more, preferably 25% or more, more preferably 50% or more, even more preferably 60% or more, and particularly preferably 70% or more compared to a differentiated cell culture. Furthermore, "suppressing the decrease of therapeutically useful physiologically active substances" means maintaining the amount of these substances present or produced (secreted) in an increased state compared to differentiated cell cultures. The degree of increase is not particularly limited as long as it exceeds the margin of error, but for example, it is 1.2 times or more, preferably 1.5 times or more, more preferably 2 times or more, and even more preferably 3 times or more compared to differentiated cell cultures.
炎症性サイトカインまたは治療上有用な生理活性物質の量は、遺伝子レベルでは、例えば、ノーザンブロッティング法、サザンブロッティング法、ＲＮａｓｅプロテクションアッセイ、ＲＴ－ＰＣＲ、リアルタイムＰＣＲ等のＰＣＲ法、in situハイブリダイゼーション法、in vitro転写法等の任意の公知の遺伝子発現解析法により、また、タンパク質レベルでは、免疫沈降法、ウェスタンブロッティング法、ＥＩＡ、ＥＬＩＳＡ、ＲＩＡ、免役組織化学法、免疫細胞化学法等の任意の公知のタンパク質検出法により検出することができる。検体としては、細胞培養物が含浸された培地や、細胞培養物の一部などを用いることができる。 The amount of inflammatory cytokines or therapeutically useful physiologically active substances can be detected at the gene level by any known gene expression analysis method, such as Northern blotting, Southern blotting, RNase protection assay, PCR such as RT-PCR and real-time PCR, in situ hybridization, in vitro transcription, etc., and at the protein level by any known protein detection method, such as immunoprecipitation, Western blotting, EIA, ELISA, RIA, immunohistochemistry, immunocytochemistry, etc. Samples that can be used include culture media impregnated with cell cultures and parts of cell cultures.
以下に、本発明を実施例に基づいてさらに説明するが、かかる実施例は、本発明の例示であり、本発明を限定するものではない。また、下記実施例においては、特に別記しない限り、骨格筋芽細胞はヒト由来のものであり、細胞の培養は３７℃、５％ＣＯ２の条件で行うものとする。 The present invention will be further described below based on examples, but these examples are illustrative of the present invention and do not limit the present invention. In the following examples, unless otherwise specified, the skeletal myoblasts are of human origin and the cells are cultured under conditions of 37°C and 5% CO2 .
実施例１ 播種密度／血清被覆処理によるシート状細胞培養物の強度への影響
温度応答性培養皿（２４ウェルプレート、セルシード製）を用意し、一部のウェルには血清を含有する培地（ＤＭＥＭ／Ｆ１２に２０％のヒト血清（Cambrex製または研究採血由来）を含むもの、以下、血清含有培地と記す）を添加し、３７℃、５％ＣＯ２の条件でインキュベートすることにより、血清被覆処理を施した。次に骨格筋芽細胞（Lonza製）を血清含有培地に懸濁し、血清を被覆した培養皿、もしくは無処理の培養皿に３．５×１０５、１．０×１０６、１．４×１０６、１．７×１０６、３．４×１０６個／ｃｍ２の各密度で播種した。２４時間培養後、温度応答性培養皿より細胞培養物を剥離し、シート形成の可否およびその強度について評価した。その結果、無処理の培養皿を用いた場合には、１．０×１０６個／ｃｍ２を超える密度で播種した場合、播種された細胞が完全にシートを形成する以前に剥離が生じ、十分な強度を有するシート状細胞培養物を形成することができなかった。一方、血清を被覆処理した培養皿を使用した場合には自然に剥離することなくシート状細胞培養物を形成することが可能であった。なお、細胞播種密度３．４×１０６個／ｃｍ２ではシート状細胞培養物を得ることができなかった。
Example 1: Influence of Seeding Density/Serum Coating Treatment on the Strength of Sheet-Shaped Cell Cultures A temperature-responsive culture dish (24-well plate, CellSeed) was prepared, and serum-containing medium (DMEM/F12 containing 20% human serum (Cambrex or from blood collected for research), hereinafter referred to as serum-containing medium) was added to some wells, and serum coating treatment was performed by incubating at 37°C and 5% CO2 . Next, skeletal myoblasts (Lonza) were suspended in serum-containing medium and seeded at densities of 3.5 x 105 , 1.0 x 106 , 1.4 x 106 , 1.7 x 106 , and 3.4 x 106 cells/ cm2 on serum-coated or untreated culture dishes. After 24 hours of culture, the cell culture was peeled off from the temperature-responsive culture dish, and the possibility of sheet formation and its strength were evaluated. As a result, when an untreated culture dish was used and the seeded cells were seeded at a density exceeding 1.0 x 106 cells/ cm2 , detachment occurred before the seeded cells completely formed a sheet, and a sheet-shaped cell culture with sufficient strength could not be formed. On the other hand, when a serum-coated culture dish was used, a sheet-shaped cell culture could be formed without spontaneous detachment. Note that a sheet-shaped cell culture could not be obtained at a cell seeding density of 3.4 x 106 cells/ cm2 .
さらに、上記と同様に血清被覆処理を施した、または施さない温度応答性培養皿（φ３．５ｃｍ、セルシード製）を用意し、骨格筋芽細胞を血清含有培地に懸濁して３．５×１０５個／ｃｍ２の密度で播種した。２４時間培養後、温度応答性培養皿よりシート状細胞培養物を剥離し、その強度を浸漬撹拌による損傷の程度に基づいて評価したところ、血清を被覆した培養皿を用いた場合に、より強度に優れたシート状細胞培養物を得ることができた。また、剥離したシート状細胞培養物を構成する細胞数について検討したところ、血清を被覆した培養皿を用いた場合には、無処理の培養皿を用いた場合に比べより多くの細胞からシート状細胞培養物が形成されており、細胞の回収率が、無処理培養皿を用いた場合の６９．８％に比べ、９６．３％と顕著に高いことが明らかとなった（表３）。
さらに、形成されたシート状細胞培養物について、播種密度による強度を評価したところ、播種密度を増加させることにより、より強度に優れたシート状細胞培養物を得ることができた。
実施例２ 分化の評価
温度応答性培養皿（２４ウェルプレート、セルシード製）を用意し、一部のウェルには、実施例１と同様に血清の被覆処理を施した。次に骨格筋芽細胞を血清含有培地に懸濁し、血清を被覆したウェル、もしくは無処理のウェルに１．０×１０６、１．４×１０６、１．７×１０６個／ｃｍ２の各密度で播種した。２４時間培養後、形成されたシート状細胞培養物からタンパク質を抽出し、クレアチンキナーゼ（ＣＫ）の活性を測定した。ＣＫは骨格筋の分化指標の１つであり、分化が進むとＣＫの活性が高値を示す。具体的には、まず形成されたシート状細胞培養物に細胞可溶化試薬（CelLyticM、sigma製）と、プロテアーゼ阻害剤（Protease Inhibitor Cocktail、sigma社）とを加え、シェーカーで振とうしながら室温で１５分間インキュベートした。細胞可溶化液を回収し、４℃、１５０００ｇの条件で１５分間遠心し、上清を回収してタンパク質抽出液とし、測定に供した。ＣＫ活性の測定は、EnzyChromTM Creatine Kinase Assay Kit（BioAssay Systems製）を使用し、添付のプロトコールに従って行った。また、抽出液のタンパク質濃度をＢＣＡ法により測定し、タンパク濃度あたりのＣＫ活性値を算出した。測定の結果、血清を被覆した培養皿を用いたシート状細胞培養物では、播種細胞密度を増加させても活性の上昇は認められず、分化の進行はみられなかった（図１）。
Example 2 Evaluation of Differentiation A temperature-responsive culture dish (24-well plate, CellSeed) was prepared, and some wells were coated with serum in the same manner as in Example 1. Skeletal myoblasts were then suspended in serum-containing medium and seeded at densities of 1.0 x 10 6 , 1.4 x 10 6 , and 1.7 x 10 6 cells/cm 2 in serum-coated or untreated wells. After 24 hours of culture, proteins were extracted from the formed sheet-like cell culture, and creatine kinase (CK) activity was measured. CK is one of the differentiation indicators of skeletal muscle, and CK activity increases as differentiation progresses. Specifically, a cell solubility reagent (CelLyticM, Sigma) and a protease inhibitor (Protease Inhibitor Cocktail, Sigma) were first added to the formed sheet-like cell culture, and the mixture was incubated at room temperature for 15 minutes while shaking with a shaker. The cell lysate was collected, centrifuged at 4°C and 15000g for 15 minutes, and the supernatant was collected to obtain a protein extract, which was then subjected to measurement. CK activity was measured using an EnzyChrom ™ Creatine Kinase Assay Kit (manufactured by BioAssay Systems) according to the attached protocol. The protein concentration of the extract was measured by the BCA method, and the CK activity value per protein concentration was calculated. As a result of the measurement, in the sheet-shaped cell culture using the serum-coated culture dish, no increase in activity was observed even when the seeding cell density was increased, and no progress of differentiation was observed (Figure 1).
実施例３ 液性因子の測定
温度応答性培養皿（φ３．５ｃｍ、セルシード製）に骨格筋芽細胞を３．５×１０５個／ｃｍ２の密度で播種し、４日間培養した後に培養上清を回収した（未分化シート状細胞培養物上清）。また、温度応答性培養皿に播種した骨格筋芽細胞を分化誘導培地（ＤＭＥＭ２００ｍｌに１００μｇ／ｍｌのＩＧＦ－１を１００μｌ、７．５％のＢＳＡ溶液を２．６ｍｌ混合したもの）にて４日間培養することにより多核化細胞（分化した細胞）とした後、さらに４日間培養して多核化細胞の培養上清を回収した（多核化シート状細胞培養物上清）。抗体アレイ（RayBio(R) Human Cytokine Antibody Array G Series 2000、RayBiotech製）を用いて、未分化シート状細胞培養物および多核化シート状細胞培養物の培養上清中に含まれる液性因子の測定を行った。その結果、多核化シート状細胞培養物では骨格筋芽シート状細胞培養物に比べてＩＬ－１α、ＩＬ－４、ＩＬ－５、ＩＬ－１３などの炎症性サイトカインの産生が多いことが明らかとなった（図２）。ＩＬ－１αは炎症反応の誘導、Ｔ細胞やＢ細胞の活性化に関与し、ＩＬ－４、ＩＬ－１３はＢ細胞の活性化や抗体産生を誘導し、ＩＬ－５は主として好酸球の活性化に働くが、いずれもアレルギー反応の誘導に関わりの深いサイトカインである。
Example 3 : Measurement of humoral factors Skeletal myoblasts were seeded on a temperature-responsive culture dish (φ3.5 cm, CellSeed) at a density of 3.5× 105 cells/ cm2 , and cultured for 4 days, after which the culture supernatant was collected (undifferentiated sheet-shaped cell culture supernatant). In addition, the skeletal myoblasts seeded on the temperature-responsive culture dish were cultured for 4 days in a differentiation-inducing medium (a mixture of 200 ml of DMEM, 100 μl of 100 μg/ml IGF-1, and 2.6 ml of 7.5% BSA solution) to form multinucleated cells (differentiated cells), and then cultured for another 4 days to collect the culture supernatant of the multinucleated cells (multinucleated sheet-shaped cell culture supernatant). Using an antibody array (RayBio (R) Human Cytokine Antibody Array G Series 2000, RayBiotech), humoral factors contained in the culture supernatant of the undifferentiated sheet-shaped cell culture and the multinucleated sheet-shaped cell culture were measured. As a result, it was revealed that the multinucleated sheet cell culture produced greater amounts of inflammatory cytokines, such as IL-1α, IL-4, IL-5, and IL-13, than the skeletal myoblast sheet cell culture (Figure 2). IL-1α is involved in the induction of inflammatory responses and the activation of T cells and B cells, IL-4 and IL-13 activate B cells and induce antibody production, and IL-5 mainly works to activate eosinophils; all of these cytokines are closely related to the induction of allergic responses.
また、幹細胞移植における有効性メカニズムの１つとして考えられている各種液性因子については、未分化シート状細胞培養物において多核化シート状細胞培養物と比較してＰＤＧＦ－ＡＢ、ＰＤＧＦ－ＢＢといった有効性に関わる作用を有する因子の産生が顕著に多いことが明らかとなった（図３）。
したがって、培養皿表面を血清で被覆した場合、細胞の播種数を多くしてもシート状細胞培養物の形成が可能であり、さらに治療上有効に作用する因子の産生が期待される。
Furthermore, with regard to various humoral factors that are thought to be one of the mechanisms behind the effectiveness of stem cell transplants, it was revealed that undifferentiated sheet-shaped cell cultures produced significantly more factors with effects related to efficacy, such as PDGF-AB and PDGF-BB, compared to multinucleated sheet-shaped cell cultures (Figure 3).
Therefore, when the surface of a culture dish is coated with serum, it is possible to form a sheet-shaped cell culture even when a large number of cells are seeded, and further, production of factors that have an effective therapeutic effect is expected.
Claims (3)
（ｉ）培養基材上に、骨格筋芽細胞を３．５×１０５個／ｃｍ２以上、３．４×１０６個／ｃｍ２未満で播種する工程、
（ｉｉ）播種された細胞を分化誘導して多核化する工程、および
（ｉｉｉ）多核化した細胞からシート状細胞培養物を形成する工程
を含み、分化誘導が、ＩＧＦ－１およびＢＳＡ（ウシ血清アルブミン）を含む分化誘導培地を用いる、前記方法。 A method for producing a sheet-shaped cell culture containing multinucleated cells, comprising the steps of:
(i) seeding skeletal myoblasts on a culture substrate at a density of 3.5 x 10 cells/cm or more and less than 3.4 x 10 cells/ cm ;
(ii) inducing differentiation of the seeded cells to cause them to become multinucleated; and (iii) forming a sheet-shaped cell culture from the multinucleated cells, wherein the differentiation is induced using a differentiation-inducing medium containing IGF-1 and BSA (bovine serum albumin).
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022078617A JP7486544B2 (en) | 2020-02-05 | 2022-05-12 | Method for producing sheet-shaped cell culture |
| JP2024075074A JP2024096340A (en) | 2020-02-05 | 2024-05-07 | Method for producing sheet-shaped cell culture |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2020017568A JP6872051B2 (en) | 2020-02-05 | 2020-02-05 | Method for producing sheet-shaped cell culture |
| JP2021069420A JP7074908B2 (en) | 2020-02-05 | 2021-04-16 | Method for producing sheet-shaped cell culture |
| JP2022078617A JP7486544B2 (en) | 2020-02-05 | 2022-05-12 | Method for producing sheet-shaped cell culture |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021069420A Division JP7074908B2 (en) | 2020-02-05 | 2021-04-16 | Method for producing sheet-shaped cell culture |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024075074A Division JP2024096340A (en) | 2020-02-05 | 2024-05-07 | Method for producing sheet-shaped cell culture |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022106986A JP2022106986A (en) | 2022-07-20 |
| JP7486544B2 true JP7486544B2 (en) | 2024-05-17 |
Family
ID=70801134
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020017568A Active JP6872051B2 (en) | 2020-02-05 | 2020-02-05 | Method for producing sheet-shaped cell culture |
| JP2021069420A Active JP7074908B2 (en) | 2020-02-05 | 2021-04-16 | Method for producing sheet-shaped cell culture |
| JP2022078617A Active JP7486544B2 (en) | 2020-02-05 | 2022-05-12 | Method for producing sheet-shaped cell culture |
| JP2024075074A Withdrawn JP2024096340A (en) | 2020-02-05 | 2024-05-07 | Method for producing sheet-shaped cell culture |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020017568A Active JP6872051B2 (en) | 2020-02-05 | 2020-02-05 | Method for producing sheet-shaped cell culture |
| JP2021069420A Active JP7074908B2 (en) | 2020-02-05 | 2021-04-16 | Method for producing sheet-shaped cell culture |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024075074A Withdrawn JP2024096340A (en) | 2020-02-05 | 2024-05-07 | Method for producing sheet-shaped cell culture |
Country Status (1)
| Country | Link |
|---|---|
| JP (4) | JP6872051B2 (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2005532803A (en) | 2002-07-12 | 2005-11-04 | ブラスティコン ビオテクノロギッシュ フォーシュング ゲーエムベーハー | Monocyte-derived transplant recipient-inducing cells and their preparation and use |
| JP2007528755A (en) | 2003-08-01 | 2007-10-18 | 株式会社カルディオ | 3D tissue structure |
| JP2008132126A (en) | 2006-11-28 | 2008-06-12 | Dainippon Printing Co Ltd | Cell transplant material |
| JP2012039906A (en) | 2010-08-17 | 2012-03-01 | Terumo Corp | Instrument for transferring graft |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5032508A (en) * | 1988-09-08 | 1991-07-16 | Marrow-Tech, Inc. | Three-dimensional cell and tissue culture system |
| JP5436905B2 (en) * | 2009-03-26 | 2014-03-05 | テルモ株式会社 | Method for producing sheet cell culture |
| JP5727665B2 (en) * | 2014-12-11 | 2015-06-03 | テルモ株式会社 | Method for producing sheet cell culture |
-
2020
- 2020-02-05 JP JP2020017568A patent/JP6872051B2/en active Active
-
2021
- 2021-04-16 JP JP2021069420A patent/JP7074908B2/en active Active
-
2022
- 2022-05-12 JP JP2022078617A patent/JP7486544B2/en active Active
-
2024
- 2024-05-07 JP JP2024075074A patent/JP2024096340A/en not_active Withdrawn
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2005532803A (en) | 2002-07-12 | 2005-11-04 | ブラスティコン ビオテクノロギッシュ フォーシュング ゲーエムベーハー | Monocyte-derived transplant recipient-inducing cells and their preparation and use |
| JP2007528755A (en) | 2003-08-01 | 2007-10-18 | 株式会社カルディオ | 3D tissue structure |
| JP2008132126A (en) | 2006-11-28 | 2008-06-12 | Dainippon Printing Co Ltd | Cell transplant material |
| JP2012039906A (en) | 2010-08-17 | 2012-03-01 | Terumo Corp | Instrument for transferring graft |
Also Published As
| Publication number | Publication date |
|---|---|
| JP7074908B2 (en) | 2022-05-24 |
| JP2024096340A (en) | 2024-07-12 |
| JP2022106986A (en) | 2022-07-20 |
| JP6872051B2 (en) | 2021-05-19 |
| JP2020078320A (en) | 2020-05-28 |
| JP2021106609A (en) | 2021-07-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5667357B2 (en) | Method for producing sheet cell culture | |
| JP5702060B2 (en) | Method for producing isolated sheet cell culture | |
| JP5436905B2 (en) | Method for producing sheet cell culture | |
| JP5634646B1 (en) | Method for producing sheet cell culture | |
| JP6670040B2 (en) | Method for producing sheet-shaped cell culture | |
| JP5727665B2 (en) | Method for producing sheet cell culture | |
| JP5893786B2 (en) | Method for producing sheet cell culture | |
| JP7486544B2 (en) | Method for producing sheet-shaped cell culture | |
| JP2024054301A (en) | Method for producing sheet-shaped cell culture | |
| JP5677559B2 (en) | Method for producing sheet cell culture | |
| JP6140322B2 (en) | Method for producing sheet cell culture | |
| JP6130868B2 (en) | Method for producing isolated sheet cell culture | |
| JP6657452B2 (en) | Method for producing sheet-shaped cell culture | |
| JP5770921B2 (en) | Method for producing sheet cell culture | |
| JP6490738B2 (en) | Method for producing sheet cell culture | |
| JP6546219B2 (en) | Method for producing sheet-like cell culture | |
| JP7482931B2 (en) | Manufacturing method for medical cell sheets | |
| JP6170524B2 (en) | Method for producing sheet cell culture | |
| JP5813074B2 (en) | Method for producing sheet cell culture |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220610 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220610 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230511 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230714 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230908 |
|
| RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20230908 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20230908 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20231020 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20231110 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240219 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20240405 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20240507 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7486544 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |